952 lines
No EOL
292 KiB
XML
952 lines
No EOL
292 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-toc" /><meta name="ncbi_acc" content="NBK577228" /><meta name="ncbi_domain" content="niceng145er7" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK577228/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Management of subclinical hypothyroidism - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX" /><meta name="author" content="National Guideline Centre (UK)" /><meta name="citation_title" content="Management of subclinical hypothyroidism" /><meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)" /><meta name="citation_date" content="2019/11" /><meta name="citation_author" content="National Guideline Centre (UK)" /><meta name="citation_pmid" content="35129922" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK577228/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Management of subclinical hypothyroidism" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)" /><meta name="DC.Contributor" content="National Guideline Centre (UK)" /><meta name="DC.Date" content="2019/11" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK577228/" /><meta name="og:title" content="Management of subclinical hypothyroidism" /><meta name="og:type" content="book" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK577228/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng145er7-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/niceng145er7/toc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK577228/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C21B87D72814100000000011000DA.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-toc">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="source">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/Book"><div class="meta-content fm-sec"><div class="iconblock whole_rhythm clearfix no_top_margin"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng145er7-lrg.png" alt="Cover of Management of subclinical hypothyroidism" /></a><div class="icnblk_cntnt"><h1 id="_NBK577228_"><span itemprop="name">Management of subclinical hypothyroidism</span></h1><div class="subtitle">Thyroid disease: assessment and management</div><p><b>Evidence review G</b></p><p><i>NICE Guideline, No. 145</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Centre (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2019 Nov</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3595-6</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div></div></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="ch7.s1"><h2 id="_ch7_s1_">Management of subclinical hypothyroidism</h2><div id="ch7.s1.1"><h3>1.1. Review question: What is the clinical and cost-effectiveness of treating subclinical hypothyroidism?</h3></div><div id="ch7.s1.2"><h3>1.2. Introduction</h3><p>Subclinical hypothyroidism (SCH) is a biochemical state in which the serum thyroid stimulating hormone (TSH) is elevated above the reference range whilst the concentrations of circulating free thyroid hormones (FT4, FT3) are within the reference range for the population. It is more common in women and becomes increasingly prevalent with age, such that around 5% of people over 70 years of age, and 10% of people over 80 may manifest SCH.</p><p>In some people SCH may be a transient phenomenon reflecting non-thyroidal illness or drug effects, but in others it may be an early manifestation of a disease process such as Hashimoto thyroiditis - in this situation the biochemical picture represents a state of compensated or mild hypothyroidism in which the circulating thyroid hormones remain within the reference range owing to increased thyroid gland stimulation by TSH.</p><p>As serum free thyroid hormones are within the reference range for the population in SCH there is uncertainty as to whether people benefit from increasing their circulating thyroid hormones with replacement therapy. Symptoms of hypothyroidism are non-specific and common in the euthyroid population, meaning that clinicians cannot be confident they have treated symptoms caused by hypothyroidism in someone with SCH. This leaves open several questions about the optimal management of people with persistent SCH.</p></div><div id="ch7.s1.3"><h3>1.3. PICO table</h3><p>For full details see the review protocol in <a href="#ch7.appa">Appendix A</a>:.</p></div><div id="ch7.s1.4"><h3>1.4. Clinical evidence</h3><div id="ch7.s1.4.1"><h4>1.4.1. Included studies</h4><p>Six RCTs were included in the review;<a class="bk_pop" href="#ch7.ref19"><sup>19</sup></a><sup>,</sup><a class="bk_pop" href="#ch7.ref24"><sup>24</sup></a><sup>,</sup><a class="bk_pop" href="#ch7.ref28"><sup>28</sup></a><sup>,</sup><a class="bk_pop" href="#ch7.ref34"><sup>34</sup></a><sup>,</sup><a class="bk_pop" href="#ch7.ref35"><sup>35</sup></a><sup>,</sup><a class="bk_pop" href="#ch7.ref40"><sup>40</sup></a> these are summarised in <a class="figpopup" href="/books/NBK577228/table/ch7.tab2/?report=objectonly" target="object" rid-figpopup="figch7tab2" rid-ob="figobch7tab2">Table 2</a> below. Evidence from these studies is summarised in the clinical evidence summary below (<a class="figpopup" href="/books/NBK577228/table/ch7.tab3/?report=objectonly" target="object" rid-figpopup="figch7tab3" rid-ob="figobch7tab3">Table 3</a>). One Cochrane review was identified in this area<a class="bk_pop" href="#ch7.ref45"><sup>45</sup></a>, the studies included in this publication were checked against the protocol and were not included in this review.</p><p>All six RCTs compared T4 with placebo.</p><p>No relevant clinical trials comparing T3, natural thyroid extract, and iodine or selenium supplementation with any other intervention or placebo were identified.</p><p>Five included studies were in the adult (18–65) age stratum, whereas one study was in the older adult (>65) age stratum.<a class="bk_pop" href="#ch7.ref40"><sup>40</sup></a> The majority of participants were female in four studies;<a class="bk_pop" href="#ch7.ref28"><sup>28</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref34"><sup>34</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref35"><sup>35</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref40"><sup>40</sup></a> whereas, the remaining two studies were conducted exclusively on female participants.<a class="bk_pop" href="#ch7.ref19"><sup>19</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref24"><sup>24</sup></a> Four RCTs were conducted on a treatment naïve population. In one RCT participants having received thyroid medication in the past 3 months were excluded<a class="bk_pop" href="#ch7.ref24"><sup>24</sup></a> whereas whether participants had received previous treatment was not specified in one RCT<a class="bk_pop" href="#ch7.ref35"><sup>35</sup></a> The primary cause of subclinical hypothyroidism was autoimmune thyroiditis in at least four studies<a class="bk_pop" href="#ch7.ref19"><sup>19</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref24"><sup>24</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref34"><sup>34</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref35"><sup>35</sup></a>; whereas this was not reported in the remaining two studies.<a class="bk_pop" href="#ch7.ref28"><sup>28</sup></a><sup>,</sup>
|
||
<a class="bk_pop" href="#ch7.ref40"><sup>40</sup></a></p><p>The follow-up period of the included studies was from 3 to 12 months.</p><p>See also the study selection flow chart in <a href="#ch7.appc">Appendix C</a>:, study evidence tables in <a href="#ch7.appd">Appendix D</a>:, forest plots in <a href="#ch7.appe">Appendix E</a>: and GRADE tables in <a href="#ch7.appf">Appendix F</a>:.</p></div><div id="ch7.s1.4.2"><h4>1.4.2. Excluded studies</h4><p>See the excluded studies list in <a href="#ch7.appj">Appendix J</a>:.</p></div><div id="ch7.s1.4.3"><h4>1.4.3. Summary of clinical studies included in the evidence review</h4><p>See <a href="#ch7.appd">Appendix D</a>: for full evidence tables.</p></div><div id="ch7.s1.4.4"><h4>1.4.4. Quality assessment of clinical studies included in the evidence review</h4><p>See <a href="#ch7.appf">Appendix F</a>: for full GRADE tables.</p></div></div><div id="ch7.s1.5"><h3>1.5. Economic evidence</h3><div id="ch7.s1.5.1"><h4>1.5.1. Included studies</h4><p>No relevant health economic studies were identified.</p></div><div id="ch7.s1.5.2"><h4>1.5.2. Excluded studies</h4><p>No health economic studies that were relevant to this question were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#ch7.appg">appendix G</a>.</p></div><div id="ch7.s1.5.3"><h4>1.5.3. Health economic modelling</h4><p>This area was not prioritised for new cost-effectiveness analysis.</p></div><div id="ch7.s1.5.4"><h4>1.5.4. Resource costs</h4><p>Relevant unit costs are provided below to aid consideration of cost effectiveness.</p></div></div><div id="ch7.s1.6"><h3>1.6. Evidence statements</h3><div id="ch7.s1.6.1"><h4>1.6.1. Clinical evidence statements</h4><div id="ch7.s1.6.1.1"><h5>1.6.1.1. Levothyroxine vs placebo in adults</h5><p>No clinically important difference was identified for hypothyroid dependent quality of life (1 study, moderate quality), quality of life measures: general health, physical functioning, social functioning (1 study, very low quality), for depression (2 studies, moderate quality), hypothyroid symptoms (2 studies, high quality) and TSH suppression (2 studies, very low quality).</p><p>There was a clinically important benefit of levothyroxine for quality of life measures: role physical functioning and bodily pain (1 study, moderate quality), and role emotional functioning (1 study, low quality).</p><p>There was a clinically important harm of levothyroxine for quality of life-mental health and vitality (1 study, very low quality).</p><p>No evidence was identified for mortality; cardiovascular morbidity-ischemic heart disease; heart failure; arrhythmias; osteoporosis; impaired cognitive function; experience of care; healthcare contacts; growth.</p></div><div id="ch7.s1.6.1.2"><h5>1.6.1.2. Levothyroxine vs placebo in older adults</h5><p>No clinically important difference was identified for quality of life measured by the EQ-5D (1 study, moderate quality), quality of life measured by the EQ VAS, hypothyroid symptoms and hyperthyroid symptoms (1 study, high quality).</p><p>No evidence was identified for mortality; cardiovascular morbidity-ischemic heart disease; heart failure; arrhythmias; osteoporosis; impaired cognitive function; depression; experience of care; healthcare contacts; growth; TSH suppression.</p></div></div><div id="ch7.s1.6.2"><h4>1.6.2. Health economic evidence statements</h4><ul id="ch7.l4"><li id="ch7.lt16" class="half_rhythm"><div>No relevant economic evaluations were identified.</div></li></ul></div></div><div id="ch7.s1.7"><h3>1.7. The committee’s discussion of the evidence</h3><div id="ch7.s1.7.1"><h4>1.7.1. Interpreting the evidence</h4><div id="ch7.s1.7.1.1"><h5>1.7.1.1. The outcomes that matter most</h5><p>The committee agreed that the critical outcomes for this review were mortality and quality of life. Important outcomes were cardiovascular morbidity, arrhythmias, osteoporosis, impaired cognitive function, depression, experience of care, healthcare contacts, symptom scores, growth and TSH suppression.</p><p>No clinical evidence was found for mortality. Thus, it was agreed that decision making would be based on quality of life and the important outcomes for which evidence was available.</p></div><div id="ch7.s1.7.1.2"><h5>1.7.1.2. The quality of the evidence</h5><p>The quality of the evidence ranged from very low to high, being of very low quality for the majority of outcomes. Evidence was typically downgraded for risk of bias which was often attributed to selection bias. Across comparisons, evidence for certain outcomes was also downgraded for imprecision. Overall, the studies included in this review were of relatively short term follow-up, with participants followed up for up to 12 months, while they were receiving the interventions.</p><div id="ch7.s1.7.1.2.1"><h5>Levothyroxine vs placebo in adults</h5><p>The quality of evidence for the use of levothyroxine compared to placebo in adults ranged from very low to high, the majority being of very low quality. The evidence was downgraded mostly due to risk of bias and occasionally due to imprecision. Studies relative to the adult age stratum had a follow up ranging from three to 12 months.</p></div><div id="ch7.s1.7.1.2.2"><h5>Levothyroxine vs placebo in older adults</h5><p>The quality of the majority of the evidence for the use of levothyroxine compared to placebo in older adults was high with the exception of one outcome for which the quality of the evidence was moderate and downgraded due to imprecision. Within this comparison, participants of the older age stratum were followed up for 12 months.</p></div></div><div id="ch7.s1.7.1.3"><h5>1.7.1.3. Benefits and harms</h5><div id="ch7.s1.7.1.3.1"><h5>Levothyroxine vs placebo in adults</h5><p>The evidence showed there was a clinically important benefit with levothyroxine compared to placebo for three quality of life domains: role-physical, role-emotional and bodily pain.</p><p>The evidence also showed that there was a clinically important harm with levothyroxine compared to placebo in terms of two quality of life domains, mental health and vitality.</p><p>No clinically important difference was found as a result of levothyroxine treatment compared to placebo for hypothyroid dependent quality of life, three quality of life domains: general health, physical functioning and social functioning, depression, hypothyroid symptoms and TSH suppression.</p><p>The committee noted that the absence of a clinically important effect could be at least partially attributed to the relatively short-term follow up periods of the studies included in this comparison, which ranged from three to 12 months. They felt that this was likely to be insufficient to observe a clinical difference that is likely to emerge later after treatment. Particularly in regards to depression and symptoms, there was agreement that a longer follow up would be required to draw conclusions about the effect of treatment with levothyroxine for adults with subclinical hypothyroidism.</p><p>It was also noted that the dosing strategies of some studies included low doses of levothyroxine that did not reflect current UK practice (starting dose is typically around 100 µg/d), and that this may undermine the effect of levothyroxine on the outcomes measured in the current evidence.</p><p>The committee noted the variability in the baseline TSH levels of patients in the studies included in this review. They specified that a TSH greater than 10 mlU/litre would be much less likely to normalise than a lower TSH and agreed on the appropriateness of using this cut off to determine treatment with levothyroxine.</p><p>It was raised that an overreliance on TSH levels in decision making about treatment that is most often the case in clinical practice may be problematic, and that other factors, including patients’ symptomatology are to influence their need for treatment. The committee felt that a trial period of treatment of 6 months would be appropriate for symptomatic patients with TSH lower than the 10 mlU/litre cut-off.</p><p>The importance of making recommendations for both providing but also stopping treatment, in cases where no apparent benefit in symptoms is achieved was emphasised. There was agreement that whether or not TSH returns to normal is a factor indicating the success of treatment but that symptoms are also important.</p><p>The committee highlighted that the presence of antibodies may also influence the likelihood of TSH to return to normal. Within this context, the committee agreed on the importance of considering factors including antibody status and previous thyroid surgery that may suggest an underlying thyroid disease when it comes to the decision of whether or not to offer treatment for subclinical hypothyroidism.</p></div><div id="ch7.s1.7.1.3.2"><h5>Levothyroxine vs placebo in older adults</h5><p>Compared to placebo, treatment with levothyroxine did not lead to a clinically important difference in two separate quality of life measures, hypothyroid symptoms and hyperthyroid symptoms.</p><p>The committee noted that the evidence for the use of levothyroxine in older adults was underpinned by one study and that a considerable proportion of the participants in this study were asymptomatic and identified based on incidental findings. The committee agreed that it was plausible that the benefits of treatment would be greater in those who had symptoms at baseline.</p></div></div></div><div id="ch7.s1.7.2"><h4>1.7.2. Cost effectiveness and resource use</h4><p>There was no health economic evidence identified for this review question, therefore recommendations were based on consensus around treating subclinical hypothyroidism. Unit costs were presented for different doses of levothyroxine as found in the included clinical studies to aid the committee members in their qualitative judgement in regards to the cost effectiveness.</p><div id="ch7.s1.7.2.1"><h5>Levothyroxine vs placebo in adults</h5><p>Although the quality of life evidence was mixed the committee thought that targeting treatment at specific groups that were more likely to benefit would maximise the likelihood of treatment being cost effective.. Overall, treating symptomatic patients compared to treating patients according to their TSH levels only, is likely to be cost saving. Firstly, because only those who need treatment will be considered, this reduces the number of people being treated unnecessarily, and secondly, people who are considered for treatment will receive a 6 month trial of treatment, after which they will be re-assessed and if no improvement is seen treatment can be stopped. This reduces prescriptions, unnecessary continuation of treatment, compliance issues, and costs.</p><p>Furthermore, the committee noted that the current practice for treating subclinical hypothyroidism is done by giving 100µcg daily of levothyroxine tablet (£1.03 per month, BNF, December 2017), which is the cheapest treatment option.</p></div><div id="ch7.s1.7.2.2"><h5>Levothyroxine vs placebo in older adults</h5><p>The committee did not recommend treatment with levothyroxine for older adults, other than when the TSH was above the reference range but lower than 10 mIU/litre, which is in line with current practice.</p></div></div><div id="ch7.s1.7.3"><h4>1.7.3. Other factors the committee took into account</h4><p>The committee acknowledged that patients often request treatments with selenium or iodine supplementation. Considering the lack of evidence in regards to those treatments and the frequency with which patients request them, the committee agreed to make research recommendations to investigate their effectiveness for treating subclinical hypothyroidism.</p></div></div></div><div id="ch7.rl.r1"><h2 id="_ch7_rl_r1_">References</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="ch7.ref1">Abreu
|
||
IM, Lau
|
||
E, de Sousa Pinto
|
||
B, Carvalho
|
||
D. Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocrine Connections. 2017; 6(3):188–199 [<a href="/pmc/articles/PMC5428911/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5428911</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28249936" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28249936</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="ch7.ref2">Aghili
|
||
R, Khamseh
|
||
ME, Malek
|
||
M, Hadian
|
||
A, Baradaran
|
||
HR, Najafi
|
||
L
|
||
et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Archives of Medical Science. 2012; 8(6):1096–101 [<a href="/pmc/articles/PMC3542502/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3542502</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23319987" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23319987</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="ch7.ref3">Akintola
|
||
AA, Jansen
|
||
SW, van Bodegom
|
||
D, van der Grond
|
||
J, Westendorp
|
||
RG, de Craen
|
||
AJ
|
||
et al. Subclinical hypothyroidism and cognitive function in people over 60 years: a systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2015; 7:150 [<a href="/pmc/articles/PMC4531303/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4531303</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26321946" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26321946</span></a>]</div></dd><dt>4.</dt><dd><div class="bk_ref" id="ch7.ref4">Angermayr
|
||
L, Clar
|
||
C. Iodine supplementation for preventing iodine deficiency disorders in children. Cochrane Database of Systematic Reviews
|
||
2004, Issue 2. Art. No.: CD003819. DOI: 10.1002/14651858.CD003819.pub2. [<a href="https://pubmed.ncbi.nlm.nih.gov/15106221" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15106221</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.CD003819.pub2" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd><dt>5.</dt><dd><div class="bk_ref" id="ch7.ref5">Appelhof
|
||
BC, Peeters
|
||
RP, Wiersinga
|
||
WM, Visser
|
||
TJ, Wekking
|
||
EM, Huyser
|
||
J
|
||
et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. Journal of Clinical Endocrinology and Metabolism. 2005; 90(11):6296–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/16144953" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16144953</span></a>]</div></dd><dt>6.</dt><dd><div class="bk_ref" id="ch7.ref6">BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary. Available from: <a href="https://www.evidence.nhs.uk/formulary/bnf/current" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>.evidence<wbr style="display:inline-block"></wbr>.nhs.uk/formulary/bnf/current</a> Last accessed: 04 April 2017</div></dd><dt>7.</dt><dd><div class="bk_ref" id="ch7.ref7">Cabral
|
||
MD, Teixeira
|
||
P, Soares
|
||
D, Leite
|
||
S, Salles
|
||
E, Waisman
|
||
M. Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics (Sao Paulo, Brazil). 2011; 66(8):1321–8 [<a href="/pmc/articles/PMC3161206/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3161206</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21915478" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21915478</span></a>]</div></dd><dt>8.</dt><dd><div class="bk_ref" id="ch7.ref8">Caraccio
|
||
N, Ferrannini
|
||
E, Monzani
|
||
F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2002; 87(4):1533–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/11932277" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11932277</span></a>]</div></dd><dt>9.</dt><dd><div class="bk_ref" id="ch7.ref9">Caraccio
|
||
N, Natali
|
||
A, Sironi
|
||
A, Baldi
|
||
S, Frascerra
|
||
S, Dardano
|
||
A
|
||
et al. Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. Journal of Clinical Endocrinology and Metabolism. 2005; 90(7):4057–62 [<a href="https://pubmed.ncbi.nlm.nih.gov/15855263" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15855263</span></a>]</div></dd><dt>10.</dt><dd><div class="bk_ref" id="ch7.ref10">Cassio
|
||
A, Cacciari
|
||
E, Cicognani
|
||
A, Damiani
|
||
G, Missiroli
|
||
G, Corbelli
|
||
E
|
||
et al. Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine?
|
||
Pediatrics. 2003; 111(5 Pt 1):1055–60 [<a href="https://pubmed.ncbi.nlm.nih.gov/12728088" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12728088</span></a>]</div></dd><dt>11.</dt><dd><div class="bk_ref" id="ch7.ref11">Cerbone
|
||
M, Capalbo
|
||
D, Wasniewska
|
||
M, Alfano
|
||
S, Raso
|
||
GM, Oliviero
|
||
U
|
||
et al. Effects of L-thyroxine treatment on early markers of atherosclerotic disease in children with subclinical hypothyroidism. European Journal of Endocrinology. 2016; 175(1):11–19 [<a href="https://pubmed.ncbi.nlm.nih.gov/27068687" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27068687</span></a>]</div></dd><dt>12.</dt><dd><div class="bk_ref" id="ch7.ref12">Cooper
|
||
DS, Halpern
|
||
R, Wood
|
||
LC, Levin
|
||
AA, Ridgway
|
||
EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Annals of Internal Medicine. 1984; 101(1):18–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/6428290" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6428290</span></a>]</div></dd><dt>13.</dt><dd><div class="bk_ref" id="ch7.ref13">Fadeyev
|
||
VV, Sytch
|
||
J, Kalashnikov
|
||
V, Rojtman
|
||
A, Syrkin
|
||
A, Melnichenko
|
||
G. Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease. Endocrine Practice. 2006; 12(1):5–17 [<a href="https://pubmed.ncbi.nlm.nih.gov/16524858" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16524858</span></a>]</div></dd><dt>14.</dt><dd><div class="bk_ref" id="ch7.ref14">Feller
|
||
M, Snel
|
||
M, Moutzouri
|
||
E, Bauer
|
||
DC, de Montmollin
|
||
M, Aujesky
|
||
D
|
||
et al. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA. 2018; 320(13):1349–1359 [<a href="/pmc/articles/PMC6233842/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6233842</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30285179" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30285179</span></a>]</div></dd><dt>15.</dt><dd><div class="bk_ref" id="ch7.ref15">Ineck
|
||
BA, Ng
|
||
TM. Effects of subclinical hypothyroidism and its treatment on serum lipids. Annals of Pharmacotherapy. 2003; 37(5):725–30 [<a href="https://pubmed.ncbi.nlm.nih.gov/12708952" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12708952</span></a>]</div></dd><dt>16.</dt><dd><div class="bk_ref" id="ch7.ref16">Iqbal
|
||
A, Jorde
|
||
R, Figenschau
|
||
Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. Journal of Internal Medicine. 2006; 260(1):53–61 [<a href="https://pubmed.ncbi.nlm.nih.gov/16789979" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16789979</span></a>]</div></dd><dt>17.</dt><dd><div class="bk_ref" id="ch7.ref17">Joint Formulary Committee. British National Formulary (BNF) December 2017 update. 2017. Available from: <a href="http://www.bnf.org.uk" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>.bnf.org.uk</a> Last accessed: 01/03/2018</div></dd><dt>18.</dt><dd><div class="bk_ref" id="ch7.ref18">Jorde
|
||
R, Waterloo
|
||
K, Storhaug
|
||
H, Nyrnes
|
||
A, Sundsfjord
|
||
J, Jenssen
|
||
TG. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. Journal of Clinical Endocrinology and Metabolism. 2006; 91(1):145–53 [<a href="https://pubmed.ncbi.nlm.nih.gov/16263815" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16263815</span></a>]</div></dd><dt>19.</dt><dd><div class="bk_ref" id="ch7.ref19">Kong
|
||
WM, Sheikh
|
||
MH, Lumb
|
||
PJ, Naoumova
|
||
RP, Freedman
|
||
DB, Crook
|
||
M
|
||
et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. American Journal of Medicine. 2002; 112(5):348–54 [<a href="https://pubmed.ncbi.nlm.nih.gov/11904108" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11904108</span></a>]</div></dd><dt>20.</dt><dd><div class="bk_ref" id="ch7.ref20">Koroglu
|
||
BK, Bagci
|
||
O, Ersoy
|
||
IH, Aksu
|
||
O, Balkarli
|
||
A, Alanoglu
|
||
E
|
||
et al. Effects of Levothyroxine Treatment on Cardiovascular Risk Profile and Carotid Intima Media Thickness in Patients with Subclinica Hypothyroidism. Acta Endocrinologica. 2012; 8(3):433–442</div></dd><dt>21.</dt><dd><div class="bk_ref" id="ch7.ref21">Li
|
||
X, Meng
|
||
Z, Jia
|
||
Q, Ren
|
||
X. Effect of L-thyroxine treatment versus a placebo on serum lipid levels in patients with sub-clinical hypothyroidism. Biomedical Reports. 2016; 5(4):443–449 [<a href="/pmc/articles/PMC5038512/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5038512</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27699011" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27699011</span></a>]</div></dd><dt>22.</dt><dd><div class="bk_ref" id="ch7.ref22">Mainenti
|
||
MR, Vigario
|
||
PS, Teixeira
|
||
PF, Maia
|
||
MD, Oliveira
|
||
FP, Vaisman
|
||
M. Effect of levothyroxine replacement on exercise performance in subclinical hypothyroidism. Journal of Endocrinological Investigation. 2009; 32(5):470–3 [<a href="https://pubmed.ncbi.nlm.nih.gov/19468264" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19468264</span></a>]</div></dd><dt>23.</dt><dd><div class="bk_ref" id="ch7.ref23">Martins
|
||
RM, Fonseca
|
||
RH, Duarte
|
||
MM, Reuters
|
||
VS, Ferreira
|
||
MM, Almeida
|
||
C
|
||
et al. Impact of subclinical hypothyroidism treatment in systolic and diastolic cardiac function. Arquivos Brasileiros de Endocrinologia e Metabologia. 2011; 55(7):460–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/22147094" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22147094</span></a>]</div></dd><dt>24.</dt><dd><div class="bk_ref" id="ch7.ref24">Meier
|
||
C, Staub
|
||
JJ, Roth
|
||
CB, Guglielmetti
|
||
M, Kunz
|
||
M, Miserez
|
||
AR
|
||
et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). Journal of Clinical Endocrinology and Metabolism. 2001; 86(10):4860–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/11600554" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11600554</span></a>]</div></dd><dt>25.</dt><dd><div class="bk_ref" id="ch7.ref25">Monzani
|
||
F, Caraccio
|
||
N, Kozakowa
|
||
M, Dardano
|
||
A, Vittone
|
||
F, Virdis
|
||
A
|
||
et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2004; 89(5):2099–106 [<a href="https://pubmed.ncbi.nlm.nih.gov/15126526" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15126526</span></a>]</div></dd><dt>26.</dt><dd><div class="bk_ref" id="ch7.ref26">Monzani
|
||
F, Di Bello
|
||
V, Caraccio
|
||
N, Bertini
|
||
A, Giorgi
|
||
D, Giusti
|
||
C
|
||
et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2001; 86(3):1110–5 [<a href="https://pubmed.ncbi.nlm.nih.gov/11238494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11238494</span></a>]</div></dd><dt>27.</dt><dd><div class="bk_ref" id="ch7.ref27">Nagasaki
|
||
T, Inaba
|
||
M, Yamada
|
||
S, Shirakawa
|
||
K, Nagata
|
||
Y, Kumeda
|
||
Y
|
||
et al. Decrease of brachial-ankle pulse wave velocity in female subclinical hypothyroid patients during normalization of thyroid function: a double-blind, placebo-controlled study. European Journal of Endocrinology. 2009; 160(3):409–15 [<a href="https://pubmed.ncbi.nlm.nih.gov/19114542" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19114542</span></a>]</div></dd><dt>28.</dt><dd><div class="bk_ref" id="ch7.ref28">Najafi
|
||
L, Malek
|
||
M, Hadian
|
||
A, Ebrahim Valojerdi
|
||
A, Khamseh
|
||
ME, Aghili
|
||
R. Depressive symptoms in patients with subclinical hypothyroidism-the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocrine Research. 2015; 40(3):121–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/25775223" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25775223</span></a>]</div></dd><dt>29.</dt><dd><div class="bk_ref" id="ch7.ref29">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>.nice.org.uk<wbr style="display:inline-block"></wbr>/article/PMG20/chapter<wbr style="display:inline-block"></wbr>/1%20Introduction%20and%20overview</a></div></dd><dt>30.</dt><dd><div class="bk_ref" id="ch7.ref30">Ng
|
||
SM, Anand
|
||
D, Weindling
|
||
AM. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. Cochrane Database of Systematic Reviews
|
||
2009, Issue 1. Art. No.: CD006972. DOI: 10.1002/14651858.CD006972.pub2. [<a href="/pmc/articles/PMC7387754/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7387754</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19160309" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19160309</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.CD006972.pub2" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd><dt>31.</dt><dd><div class="bk_ref" id="ch7.ref31">Nystrom
|
||
E, Caidahl
|
||
K, Fager
|
||
G, Wikkelso
|
||
C, Lundberg
|
||
PA, Lindstedt
|
||
G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clinical Endocrinology. 1988; 29(1):63–75 [<a href="https://pubmed.ncbi.nlm.nih.gov/3073880" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3073880</span></a>]</div></dd><dt>32.</dt><dd><div class="bk_ref" id="ch7.ref32">Parle
|
||
J, Roberts
|
||
L, Wilson
|
||
S, Pattison
|
||
H, Roalfe
|
||
A, Haque
|
||
MS
|
||
et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. Journal of Clinical Endocrinology and Metabolism. 2010; 95(8):3623–32 [<a href="https://pubmed.ncbi.nlm.nih.gov/20501682" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20501682</span></a>]</div></dd><dt>33.</dt><dd><div class="bk_ref" id="ch7.ref33">Pollock
|
||
MA, Sturrock
|
||
A, Marshall
|
||
K, Davidson
|
||
KM, Kelly
|
||
CJ, McMahon
|
||
AD
|
||
et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ. 2001; 323(7318):891–5 [<a href="/pmc/articles/PMC58535/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC58535</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11668132" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11668132</span></a>]</div></dd><dt>34.</dt><dd><div class="bk_ref" id="ch7.ref34">Razvi
|
||
S, Ingoe
|
||
L, Keeka
|
||
G, Oates
|
||
C, McMillan
|
||
C, Weaver
|
||
JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism. 2007; 92(5):1715–23 [<a href="https://pubmed.ncbi.nlm.nih.gov/17299073" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17299073</span></a>]</div></dd><dt>35.</dt><dd><div class="bk_ref" id="ch7.ref35">Reuters
|
||
VS, Almeida Cde
|
||
P, Teixeira Pde
|
||
F, Vigario Pdos
|
||
S, Ferreira
|
||
MM, Castro
|
||
CL
|
||
et al. Effects of subclinical hypothyroidism treatment on psychiatric symptoms, muscular complaints, and quality of life. Arquivos Brasileiros de Endocrinologia e Metabologia. 2012; 56(2):128–36 [<a href="https://pubmed.ncbi.nlm.nih.gov/22584566" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22584566</span></a>]</div></dd><dt>36.</dt><dd><div class="bk_ref" id="ch7.ref36">Ross
|
||
DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. American Journal of Medicine. 1993; 95(4):385–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/8213870" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8213870</span></a>]</div></dd><dt>37.</dt><dd><div class="bk_ref" id="ch7.ref37">Ruggeri
|
||
RM, Trimarchi
|
||
F, Biondi
|
||
B. L-Thyroxine replacement therapy in the frail elderly: A challenge in clinical practice. European Journal of Endocrinology. 2017; 177(4):R199–R217 [<a href="https://pubmed.ncbi.nlm.nih.gov/28566447" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28566447</span></a>]</div></dd><dt>38.</dt><dd><div class="bk_ref" id="ch7.ref38">Segna
|
||
D, Bauer
|
||
DC, Feller
|
||
M, Schneider
|
||
C, Fink
|
||
HA, Aubert
|
||
CE
|
||
et al. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. Journal of Internal Medicine. 2017; 283(1):56–72 [<a href="/pmc/articles/PMC5739958/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5739958</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29034571" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29034571</span></a>]</div></dd><dt>39.</dt><dd><div class="bk_ref" id="ch7.ref39">Shatynska-Mytsyk
|
||
I, Rodrigo
|
||
L, Cioccocioppo
|
||
R, Petrovic
|
||
D, Lakusic
|
||
N, Compostella
|
||
L
|
||
et al. The impact of thyroid hormone replacement therapy on left ventricular diastolic function in patients with subclinical hypothyroidism. Journal of Endocrinological Investigation. 2016; 39(6):709–713 [<a href="https://pubmed.ncbi.nlm.nih.gov/25740068" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25740068</span></a>]</div></dd><dt>40.</dt><dd><div class="bk_ref" id="ch7.ref40">Stott
|
||
DJ, Rodondi
|
||
N, Kearney
|
||
PM, Ford
|
||
I, Westendorp
|
||
RGJ, Mooijaart
|
||
SP
|
||
et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. New England Journal of Medicine. 2017; 376(26):2534–2544 [<a href="https://pubmed.ncbi.nlm.nih.gov/28402245" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28402245</span></a>]</div></dd><dt>41.</dt><dd><div class="bk_ref" id="ch7.ref41">Sun
|
||
J, Yao
|
||
L, Fang
|
||
Y, Yang
|
||
R, Chen
|
||
Y, Yang
|
||
K
|
||
et al. Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. International Journal of Endocrinology Print. 2017; 2017:8130796 [<a href="/pmc/articles/PMC5610794/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5610794</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29081800" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29081800</span></a>]</div></dd><dt>42.</dt><dd><div class="bk_ref" id="ch7.ref42">Taylor
|
||
PN, Okosieme
|
||
OE, Dayan
|
||
CM, Lazarus
|
||
JH. Impact of iodine supplementation in mild-to-moderate iodine deficiency: Systematic review and meta-analysis. European Journal of Endocrinology. 2014; 170(1):R1–R15 [<a href="https://pubmed.ncbi.nlm.nih.gov/24088547" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24088547</span></a>]</div></dd><dt>43.</dt><dd><div class="bk_ref" id="ch7.ref43">Teixeira
|
||
PF, Reuters
|
||
VS, Ferreira
|
||
MM, Almeida
|
||
CP, Reis
|
||
FA, Melo
|
||
BA
|
||
et al. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. Hormone and Metabolic Research. 2008; 40(1):50–5 [<a href="https://pubmed.ncbi.nlm.nih.gov/18085502" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18085502</span></a>]</div></dd><dt>44.</dt><dd><div class="bk_ref" id="ch7.ref44">Valizadeh
|
||
M, Seyyedmajidi
|
||
MR, Momtazi
|
||
S, Musavi Nasab
|
||
N. The efficacy of combined levothyroxine plus liothyronine with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Iranian journal of endocrinology and metabolism. 2009; 10(5):465–471</div></dd><dt>45.</dt><dd><div class="bk_ref" id="ch7.ref45">Villar
|
||
HCCE, Saconato
|
||
H, Valente
|
||
O, Atallah
|
||
ÁN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database of Systematic Reviews
|
||
2007, Issue 3. Art. No.: CD003419. DOI: 10.1002/14651858.CD003419.pub2. [<a href="/pmc/articles/PMC6610974/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6610974</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17636722" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17636722</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.CD003419.pub2" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd><dt>46.</dt><dd><div class="bk_ref" id="ch7.ref46">Wasniewska
|
||
M, Corrias
|
||
A, Aversa
|
||
T, Valenzise
|
||
M, Mussa
|
||
A, De Martino
|
||
L
|
||
et al. Comparative evaluation of therapy with L-thyroxine versus no treatment in children with idiopathic and mild subclinical hypothyroidism. Hormone research in pdiatrics. 2012; 77(6):376–81 [<a href="https://pubmed.ncbi.nlm.nih.gov/22699818" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22699818</span></a>]</div></dd><dt>47.</dt><dd><div class="bk_ref" id="ch7.ref47">Yazici
|
||
M, Gorgulu
|
||
S, Sertbas
|
||
Y, Erbilen
|
||
E, Albayrak
|
||
S, Yildiz
|
||
O
|
||
et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. International Journal of Cardiology. 2004; 95(2–3):135–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/15193811" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15193811</span></a>]</div></dd><dt>48.</dt><dd><div class="bk_ref" id="ch7.ref48">Yetmis
|
||
M, Kazancioglu
|
||
R, Erkoc
|
||
R, Tukek
|
||
T, Peru
|
||
C, Cikrkcioglu
|
||
MA. Changes in lipid profile and body mass index in patients with subclinical hypothyroidism: Evaluation of L-Thyroxine treatment. Haseki Tip Bulteni. 2011; 49(4):131–135</div></dd><dt>49.</dt><dd><div class="bk_ref" id="ch7.ref49">Zhao
|
||
M, Liu
|
||
L, Wang
|
||
F, Yuan
|
||
Z, Zhang
|
||
X, Xu
|
||
C
|
||
et al. A Worthy Finding: Decrease in Total Cholesterol and Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical Hypothyroidism. Thyroid. 2016; 26(8):1019–29 [<a href="https://pubmed.ncbi.nlm.nih.gov/27270263" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27270263</span></a>]</div></dd><dt>50.</dt><dd><div class="bk_ref" id="ch7.ref50">Zhao
|
||
T, Chen
|
||
B, Zhou
|
||
Y, Wang
|
||
X, Zhang
|
||
Y, Wang
|
||
H
|
||
et al. Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: a meta-analysis. BMJ Open. 2017; 7(10):e016053 [<a href="/pmc/articles/PMC5665330/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5665330</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29061604" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29061604</span></a>]</div></dd><dt>51.</dt><dd><div class="bk_ref" id="ch7.ref51">Zhu
|
||
L, Bai
|
||
X, Teng
|
||
WP, Shan
|
||
ZY, Wang
|
||
WW, Fan
|
||
CL
|
||
et al. [Effects of selenium supplementation on antibodies of autoimmune thyroiditis]. Chinese Medical Journal (Taipei). 2012; 92(32):2256–2260 [<a href="https://pubmed.ncbi.nlm.nih.gov/23158484" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23158484</span></a>]</div></dd></dl></div><div id="appendixesappgroup7"><h2 id="_appendixesappgroup7_">Appendices</h2><div id="ch7.appa"><h3>Appendix A. Review protocols</h3><div id="ch7.appa.tab1" class="table"><h3><span class="label">Table 5</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ID</th><th id="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Field</th><th id="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">I</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">What is the clinical and cost effectiveness of treating subclinical hypothyroidism?</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">II</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Intervention</p>
|
||
<p>A review of health economic evidence related to the same review question was conducted in parallel with this review. For details see the health economic review protocol for this NICE guideline.</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">III</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Determine the most clinically and cost effective way to treat subclinical hypothyroidism</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population / disease / condition / issue / domain</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">People diagnosed with subclinical hypothyroidism (TSH greater than upper limit of context specific reference range, T3/T4 within reference range)</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T3</p>
|
||
<p>T4 – initiation at high dose</p>
|
||
<p>T4 – initiation via gradual titration</p>
|
||
<p>Combination of T3 & T4</p>
|
||
<p>Natural thyroid extract (mammalian only)</p>
|
||
<p>Iodine supplementation</p>
|
||
<p>Selenium supplementation</p>
|
||
<p>Placebo</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VI</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – comparator(s) / control or reference (gold) standard</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any of above vs any other, in isolation or combination</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical</b>
|
||
<ul id="ch7.l5"><li id="ch7.lt17" class="half_rhythm"><div>Mortality (dichotomous, ≥1 year)</div></li><li id="ch7.lt18" class="half_rhythm"><div>Quality of life (continuous)</div></li></ul>
|
||
<b>Important</b>
|
||
<ul id="ch7.l6"><li id="ch7.lt19" class="half_rhythm"><div>Cardiovascular morbidity - ischaemic heart disease, heart failure (dichotomous)</div></li><li id="ch7.lt20" class="half_rhythm"><div>Arhythmias (dichotomous)</div></li><li id="ch7.lt21" class="half_rhythm"><div>Osteoporosis (dichotomous)</div></li><li id="ch7.lt22" class="half_rhythm"><div>Impaired cognitive function/neurodevelopment for children (dichotomous)</div></li><li id="ch7.lt23" class="half_rhythm"><div>Depression (dichotomous)</div></li><li id="ch7.lt24" class="half_rhythm"><div>Patient/family/carer experience of care (continuous)</div></li><li id="ch7.lt25" class="half_rhythm"><div>Healthcare contacts (rates/dichotomous)</div></li><li id="ch7.lt26" class="half_rhythm"><div>Symptom scores (continuous)</div></li><li id="ch7.lt27" class="half_rhythm"><div>Growth (continuous)</div></li><li id="ch7.lt28" class="half_rhythm"><div>TSH suppression (dichotomous)</div></li></ul>
|
||
Minimum duration as for the minimum duration for inclusion of studies unless specified.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VIII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l7"><li id="ch7.lt29" class="half_rhythm"><div>RCTs only</div></li><li id="ch7.lt30" class="half_rhythm"><div>Blinded comparisons prioritised, non-blinded comparisons only considered if blinded unavailable on an intervention by intervention basis</div></li><li id="ch7.lt31" class="half_rhythm"><div>Minimum treatment duration of 3 months</div></li><li id="ch7.lt32" class="half_rhythm"><div>Crossover studies included</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IX</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l8"><li id="ch7.lt33" class="half_rhythm"><div>Europe based studies only for selenium supplementation to maintain representative selenium status in trial populations to UK population</div></li><li id="ch7.lt34" class="half_rhythm"><div>Studies in areas/populations of severe iodine deficiency excluded for iodine supplementation excluded</div></li><li id="ch7.lt35" class="half_rhythm"><div>Studies in pregnant women excluded</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">X</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity / subgroup analysis, or meta-regression</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Stratifications</b>
|
||
<ul id="ch7.l9"><li id="ch7.lt36" class="half_rhythm"><div>Age – children (under 4), children (4–18), adults (>18–65), older adults (>65)</div></li><li id="ch7.lt37" class="half_rhythm"><div>TSH at initiation of treatment – TSH 2.5–<5 U/ml, 5–<10 U/ml, 10 or more U/ml (only applicable to treatment naïve)</div></li></ul>
|
||
<b>Subgroup analyses</b>
|
||
<ul id="ch7.l10"><li id="ch7.lt38" class="half_rhythm"><div>Age subdivisions (18–50, 50–65, 65–80, >85)</div></li><li id="ch7.lt39" class="half_rhythm"><div>T4 treatment strategy (liquid vs pill, daily vs weekly)</div></li><li id="ch7.lt40" class="half_rhythm"><div>Children on dietary restrictions vs general diet</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XI</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening / selection / analysis</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l11"><li id="ch7.lt41" class="half_rhythm"><div>No duplicate screening was deemed necessary for this question, for more information please see the separate Methods report for this guideline.</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l12"><li id="ch7.lt42" class="half_rhythm"><div>Pairwise meta-analyses were performed using Cochrane Review Manager (RevMan5).</div></li><li id="ch7.lt43" class="half_rhythm"><div>GRADEpro was used to assess the quality of evidence for each outcome.</div></li><li id="ch7.lt44" class="half_rhythm"><div>Endnote was used for bibliography, citations, sifting and reference management</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XIII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l13"><li id="ch7.lt45" class="half_rhythm"><div>Medline, Embase and the Cochrane Library</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XIV</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an update</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XV</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10074" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>.nice.org<wbr style="display:inline-block"></wbr>.uk/guidance/indevelopment/gid-ng10074</a>
|
||
</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XVI</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an amendment</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XVII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for one database</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see <a href="#ch7.appb">Appendix B</a>:.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XVIII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms / duplicate</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format was used, and published as an appendix of the evidence report.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XIX</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see evidence tables in <a href="#ch7.appd">Appendix D</a>: (clinical evidence tables) or <a href="#ch7.apph">Appendix H</a>: (health economic evidence tables).</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XX</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome / study level</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></p>
|
||
<p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>.gradeworkinggroup.org/</a></p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXI</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for quantitative analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the separate Methods report for this guideline.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXIII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXIV</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confidence in cumulative evidence</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXV</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale / context – what is known</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXVI</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>A <a href="https://www.nice.org.uk/guidance/ng145/documents" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">multidisciplinary committee</a> developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Sarah Fishburn in line with section 3 of Developing NICE guidelines: the manual.</p>
|
||
<p>Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details please see <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXVII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding / support</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXVIII</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXIX</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England.</td></tr><tr><td headers="hd_h_ch7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXX</td><td headers="hd_h_ch7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_ch7.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered</td></tr></tbody></table></div></div><div id="ch7.appa.tab2" class="table"><h3><span class="label">Table 6</span><span class="title">Health economic review protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appa.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appa.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch7.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review question</th><th id="hd_h_ch7.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All questions – health economic evidence</th></tr></thead><tbody><tr><td headers="hd_h_ch7.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<b>Objectives</b>
|
||
</td><td headers="hd_h_ch7.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To identify health economic studies relevant to any of the review questions.</td></tr><tr><td headers="hd_h_ch7.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<b>Search criteria</b>
|
||
</td><td headers="hd_h_ch7.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l14"><li id="ch7.lt46" class="half_rhythm"><div>Populations, interventions and comparators must be as specified in the clinical review protocol above.</div></li><li id="ch7.lt47" class="half_rhythm"><div>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</div></li><li id="ch7.lt48" class="half_rhythm"><div>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</div></li><li id="ch7.lt49" class="half_rhythm"><div>Unpublished reports will not be considered unless submitted as part of a call for evidence.</div></li><li id="ch7.lt50" class="half_rhythm"><div>Studies must be in English.</div></li></ul></td></tr><tr><td headers="hd_h_ch7.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<b>Search strategy</b>
|
||
</td><td headers="hd_h_ch7.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A health economic study search will be undertaken using population-specific terms and a health economic study filter – see <a href="#ch7.appb">Appendix B</a>: below.</td></tr><tr><td headers="hd_h_ch7.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<b>Review strategy</b>
|
||
</td><td headers="hd_h_ch7.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p>
|
||
<p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in <a href="#ch7.apph">appendix H</a> of Developing NICE guidelines: the manual (2014).<a class="bk_pop" href="#ch7.ref29"><sup>29</sup></a></p>
|
||
<p><b>Inclusion and exclusion criteria</b>
|
||
<ul id="ch7.l15"><li id="ch7.lt51" class="half_rhythm"><div>If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</div></li><li id="ch7.lt52" class="half_rhythm"><div>If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</div></li><li id="ch7.lt53" class="half_rhythm"><div>If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</div></li></ul>
|
||
<b>Where there is discretion</b></p>
|
||
<p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p>
|
||
<p>The health economist will be guided by the following hierarchies.</p>
|
||
<p><i>Setting:</i>
|
||
<ul id="ch7.l16"><li id="ch7.lt54" class="half_rhythm"><div>UK NHS (most applicable).</div></li><li id="ch7.lt55" class="half_rhythm"><div>OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</div></li><li id="ch7.lt56" class="half_rhythm"><div>OECD countries with predominantly private health insurance systems (for example, Switzerland).</div></li><li id="ch7.lt57" class="half_rhythm"><div>Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
||
<i>Health economic study type:</i>
|
||
<ul id="ch7.l17"><li id="ch7.lt58" class="half_rhythm"><div>Cost–utility analysis (most applicable).</div></li><li id="ch7.lt59" class="half_rhythm"><div>Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).</div></li><li id="ch7.lt60" class="half_rhythm"><div>Comparative cost analysis.</div></li><li id="ch7.lt61" class="half_rhythm"><div>Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
||
<i>Year of analysis:</i>
|
||
<ul id="ch7.l18"><li id="ch7.lt62" class="half_rhythm"><div>The more recent the study, the more applicable it will be.</div></li><li id="ch7.lt63" class="half_rhythm"><div>Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as ‘Not applicable’.</div></li><li id="ch7.lt64" class="half_rhythm"><div>Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
||
<i>Quality and relevance of effectiveness data used in the health economic analysis:</i>
|
||
<ul id="ch7.l19"><li id="ch7.lt65" class="half_rhythm"><div>The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.</div></li></ul></p>
|
||
</td></tr></tbody></table></div></div></div><div id="ch7.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2018 <a href="https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869</a></p><p><i>For more detailed information, please see the</i> Methodology <i>Review</i>.</p><div id="ch7.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p>Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.</p><div id="ch7.appb.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_ch7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_ch7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_ch7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline (OVID)</td><td headers="hd_h_ch7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 – 07 January 2019</td><td headers="hd_h_ch7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Exclusions</p>
|
||
<p>Randomised controlled trials</p>
|
||
<p>Systematic review studies</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase (OVID)</td><td headers="hd_h_ch7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 – 07 January 2019</td><td headers="hd_h_ch7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Exclusions</p>
|
||
<p>Randomised controlled trials</p>
|
||
<p>Systematic review studies</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The Cochrane Library (Wiley)</td><td headers="hd_h_ch7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Cochrane Reviews to 2019 Issue 1 or 12</p>
|
||
<p>CENTRAL to 2019 Issue 1 or 12</p>
|
||
<p>DARE, and NHSEED to 2015 Issue 2 of 4</p>
|
||
<p>HTA to 2016 Issue 2 of 4</p>
|
||
</td><td headers="hd_h_ch7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div><div id="ch7.appb.tab2" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab2_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp thyroid diseases/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hyperthyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypothyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">thyrotoxicosis.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/7–14</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 not 16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/17–23</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 25 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((iodine or selenium) adj2 supplement*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(desiccated adj3 (thyroid or hormone* or extract or extracts)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj2 (extract or extracts)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(natural adj4 thyroid).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(natural adj3 (extract or extracts)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">armour*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroxine or levothyroxine or liothyronine or triiodothyronine or tri-iodothyronine).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Thyroxine/ or Triiodothyronine/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(T3 or T4).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(TSH or thyroid stimulating hormone or thyrotropin).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/27–36</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 and 37</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">controlled clinical trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomi#ed.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo.ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomly.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical Trials as topic.sh.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">trial.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/39–45</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-Analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Meta-Analysis as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/47–56</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38 and (46 or 57)</td></tr></tbody></table></div></div><div id="ch7.appb.tab3" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp thyroid disease/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hyperthyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypothyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">thyrotoxicosis.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/ or case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/7–11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 not 13</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/14–21</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 not 22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 23 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((iodine or selenium) adj2 supplement*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(desiccated adj3 (thyroid or hormone* or extract or extracts)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj2 (extract or extracts)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(natural adj4 thyroid).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">armour*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*thyroxine/ or *levothyroxine/ or *liothyronine/ or *triiodothyronine/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroxine or levothyroxine or liothyronine or triiodothyronine or tri-iodothyronine).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(T3 or T4).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(TSH or thyroid stimulating hormone or thyrotropin).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*thyrotropin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25–34</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 and 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">factorial*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(crossover* or cross over*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((doubl* or singl*) adj blind*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(assign* or allocat* or volunteer* or placebo*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">crossover procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">single blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">double blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/37–45</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">systematic review/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/47–56</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 and (46 or 57)</td></tr></tbody></table></div></div><div id="ch7.appb.tab4" class="table"><h3><span class="title">Cochrane Library (Wiley) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab4_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Thyroid Diseases] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hyperthyroid*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypothyroid*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">thyrotoxicosis:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid near/3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #1–#5)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((iodine or selenium) near/2 supplement*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(desiccated near/3 (thyroid or hormone* or extract or extracts)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid near/2 (extract or extracts)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(natural near/4 thyroid):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(natural near/3 (extract or extracts)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">armour*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroxine or levothyroxine or liothyronine or triiodothyronine or tri-iodothyronine):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Thyroxine] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Triiodothyronine] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(T3 or T4):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(TSH or thyroid stimulating hormone or thyrotropin):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #7–#17)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6 and #18</td></tr></tbody></table></div></div></div><div id="ch7.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p>Health economic evidence was identified by conducting a broad search relating to a thyroid disease population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics, economic modelling and quality of life studies.</p><div id="ch7.appb.tab5" class="table"><h3><span class="label">Table 7</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_ch7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_ch7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_ch7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_ch7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline</td><td headers="hd_h_ch7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014 – 07 January 2019</td><td headers="hd_h_ch7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Exclusions</p>
|
||
<p>Health economics studies</p>
|
||
<p>Health economics modelling studies</p>
|
||
<p>Quality of life studies</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase</td><td headers="hd_h_ch7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014 – 07 January 2019</td><td headers="hd_h_ch7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Exclusions</p>
|
||
<p>Health economics studies</p>
|
||
<p>Health economics modelling studies</p>
|
||
<p>Quality of life studies</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Centre for Research and Dissemination (CRD)</td><td headers="hd_h_ch7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>HTA - Inception – 07 January 2019</p>
|
||
<p>NHSEED - Inception to March 2015</p>
|
||
</td><td headers="hd_h_ch7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div><div id="ch7.appb.tab6" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab6_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp thyroid diseases/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hyperthyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypothyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">thyrotoxicosis.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/7–14</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 not 16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/17–23</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 25 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Value of life/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Costs and Cost Analysis”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Hospital/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Medical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Nursing/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Pharmaceutical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Fees and Charges”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Budgets/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/27–42</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp models, economic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Models, Theoretical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Models, Organizational/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">markov chains/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">monte carlo method/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Decision Theory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(markov* or monte carlo).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">econom* model*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(decision* adj2 (tree* or analy* or model*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/44–52</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">quality-adjusted life years/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(quality adj2 (wellbeing or well being)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">disability adjusted life.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qal* or qtime* or qwb* or daly*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(euroqol* or eq5d* or eq 5*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health utility* or utility score* or disutilit* or utility value*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(hui or hui1 or hui2 or hui3).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health* year* equivalent* or hye or hyes).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">discrete choice*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rosser.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/54–72</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 and (43 or 53 or 73)</td></tr></tbody></table></div></div><div id="ch7.appb.tab7" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab7_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp thyroid diseases/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hyperthyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypothyroid*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">thyrotoxicosis*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/ or case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/7–11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 not 13</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/14–21</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 not 22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 23 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">health economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic evaluation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp health care cost/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fee/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">funding/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25–37</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">statistical model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic aspect/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 and 40</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*theoretical model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*nonbiological model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">stochastic model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">decision theory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">decision tree/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">monte carlo method/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(markov* or monte carlo).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">econom* model*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(decision* adj2 (tree* or analy* or model*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/41–50</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">quality adjusted life year/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“quality of life index”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">short form 12/ or short form 20/ or short form 36/ or short form 8/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(quality adj2 (wellbeing or well being)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">disability adjusted life.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qal* or qtime* or qwb* or daly*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(euroqol* or eq5d* or eq 5*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health utility* or utility score* or disutilit* or utility value*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(hui or hui1 or hui2 or hui3).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health* year* equivalent* or hye or hyes).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">discrete choice*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rosser.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/52–72</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 and (38 or 51 or 73)</td></tr></tbody></table></div></div><div id="ch7.appb.tab8" class="table"><h3><span class="title">NHS EED and HTA (CRD) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appb.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appb.tab8_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Thyroid Diseases EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hyperthyroid*</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypothyroid*</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">thyrotoxicosis*</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 OR #2 OR #3 OR #4 or #5</td></tr></tbody></table></div></div></div></div><div id="ch7.appc"><h3>Appendix C. Clinical evidence selection</h3><div id="ch7.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20review%20of%20management%20of%20subclinical%20hypothyroidism.&p=BOOKS&id=577228_ch7appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the review of management of subclinical hypothyroidism." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the review of management of subclinical hypothyroidism</span></h3></div></div><div id="ch7.appd"><h3>Appendix D. Clinical evidence tables</h3><p id="ch7.appd.et1"><a href="/books/NBK577228/bin/ch7-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (1.5M)</span></p></div><div id="ch7.appe"><h3>Appendix E. Forest plots</h3><div id="ch7.appe.s1"><h4>E.1. Subclinical hypothyroidism – T4 vs placebo in Adults</h4><div id="ch7.appe.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Quality%20of%20life%3A%20hypothyroid%20dependent%20(T-QoL%2C%20%022123%20to%201%2C%20high%20%3D%20good%2C%20at%2012%20months).&p=BOOKS&id=577228_ch7appef1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef1.jpg" alt="Figure 3. Quality of life: hypothyroid dependent (T-QoL, −3 to 1, high = good, at 12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Quality of life: hypothyroid dependent (T-QoL, −3 to 1, high = good, at 12 months)</span></h3></div><div id="ch7.appe.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Quality%20of%20life%3A%20general%20health%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef2.jpg" alt="Figure 4. Quality of life: general health (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Quality of life: general health (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Quality%20of%20life%3A%20physical%20functioning%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef3.jpg" alt="Figure 5. Quality of life: physical functioning (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Quality of life: physical functioning (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Quality%20of%20life%3A%20role-physical%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef4.jpg" alt="Figure 6. Quality of life: role-physical (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Quality of life: role-physical (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Quality%20of%20life%3A%20social%20functioning%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef5.jpg" alt="Figure 7. Quality of life: social functioning (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Quality of life: social functioning (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%208.%20Quality%20of%20life%3A%20role-emotional%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef6.jpg" alt="Figure 8. Quality of life: role-emotional (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 8</span><span class="title">Quality of life: role-emotional (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%209.%20Quality%20of%20life%3A%20mental%20health%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef7.jpg" alt="Figure 9. Quality of life: mental health (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 9</span><span class="title">Quality of life: mental health (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2010.%20Quality%20of%20life%3A%20vitality%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef8.jpg" alt="Figure 10. Quality of life: vitality (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 10</span><span class="title">Quality of life: vitality (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2011.%20Quality%20of%20life%3A%20bodily%20pain%20(SF-36%2C%200%02013100%2C%20high%3Dgood%2C%20at%206%20months).&p=BOOKS&id=577228_ch7appef9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef9.jpg" alt="Figure 11. Quality of life: bodily pain (SF-36, 0–100, high=good, at 6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 11</span><span class="title">Quality of life: bodily pain (SF-36, 0–100, high=good, at 6 months)</span></h3></div><div id="ch7.appe.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2012.%20Depression%20(BDI%2C%200%0201363%2C%20high%3Dpoor%2C%20at%203%020136%20months).&p=BOOKS&id=577228_ch7appef10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef10.jpg" alt="Figure 12. Depression (BDI, 0–63, high=poor, at 3–6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 12</span><span class="title">Depression (BDI, 0–63, high=poor, at 3–6 months)</span></h3></div><div id="ch7.appe.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2013.%20Hypothyroid%20symptoms%20(Multiple%20scales%2C%20high%3Dpoor%2C%20at%206%0201312%20months).&p=BOOKS&id=577228_ch7appef11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef11.jpg" alt="Figure 13. Hypothyroid symptoms (Multiple scales, high=poor, at 6–12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 13</span><span class="title">Hypothyroid symptoms (Multiple scales, high=poor, at 6–12 months)</span></h3></div><div id="ch7.appe.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2014.%20TSH%20suppression%20(%3E%20reference%2C%20at%203%20months).&p=BOOKS&id=577228_ch7appef12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef12.jpg" alt="Figure 14. TSH suppression (> reference, at 3 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 14</span><span class="title">TSH suppression (> reference, at 3 months)</span></h3></div></div><div id="ch7.appe.s2"><h4>E.2. Subclinical hypothyroidism - T4 vs placebo for older adults</h4><div id="ch7.appe.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2015.%20Quality%20of%20life%20(EQ-5D%2C%20%022120.59%020131%2C%20high%3Dgood%2C%20at%2012%20months).&p=BOOKS&id=577228_ch7appef13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef13.jpg" alt="Figure 15. Quality of life (EQ-5D, −0.59–1, high=good, at 12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 15</span><span class="title">Quality of life (EQ-5D, −0.59–1, high=good, at 12 months)</span></h3></div><div id="ch7.appe.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2016.%20Quality%20of%20life%20(EQ%20VAS%2C%200%02013100%2C%20high%3Dgood%2C%20at%2012%20months).&p=BOOKS&id=577228_ch7appef14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef14.jpg" alt="Figure 16. Quality of life (EQ VAS, 0–100, high=good, at 12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 16</span><span class="title">Quality of life (EQ VAS, 0–100, high=good, at 12 months)</span></h3></div><div id="ch7.appe.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2017.%20Hypothyroid%20symptoms%20(ThyPRO%2C%200%02013100%2C%20high%3Dpoor%2C%20at%2012%20months).&p=BOOKS&id=577228_ch7appef15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef15.jpg" alt="Figure 17. Hypothyroid symptoms (ThyPRO, 0–100, high=poor, at 12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 17</span><span class="title">Hypothyroid symptoms (ThyPRO, 0–100, high=poor, at 12 months)</span></h3></div><div id="ch7.appe.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2018.%20Hyperthyroid%20symptoms%20(Thy-PRO%2C%200%02013100%2C%20high%3D%20poor%2C%20at%2012%20months).&p=BOOKS&id=577228_ch7appef16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appef16.jpg" alt="Figure 18. Hyperthyroid symptoms (Thy-PRO, 0–100, high= poor, at 12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 18</span><span class="title">Hyperthyroid symptoms (Thy-PRO, 0–100, high= poor, at 12 months)</span></h3></div></div></div><div id="ch7.appf"><h3>Appendix F. GRADE tables</h3><div id="ch7.appf.tab1" class="table"><h3><span class="label">Table 8</span><span class="title">Clinical evidence profile: T4 versus placebo in adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appf.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appf.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch7.appf.tab1_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch7.appf.tab1_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch7.appf.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch7.appf.tab1_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch7.appf.tab1_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch7.appf.tab1_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch7.appf.tab1_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch7.appf.tab1_1_1_1_1" id="hd_h_ch7.appf.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch7.appf.tab1_1_1_1_2" id="hd_h_ch7.appf.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">T4</th><th headers="hd_h_ch7.appf.tab1_1_1_1_2" id="hd_h_ch7.appf.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Placebo</th><th headers="hd_h_ch7.appf.tab1_1_1_1_3" id="hd_h_ch7.appf.tab1_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch7.appf.tab1_1_1_1_3" id="hd_h_ch7.appf.tab1_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Hypothyroid-dependent (follow-up 12 months; measured with: T-QoL; range of scores: −3–1; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">100</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">100</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.1 higher (0.16 lower to 0.36 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁◯</p>
|
||
<p>MODERATE</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: General health (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.9 lower (9.08 lower to 7.28 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁◯◯◯</p>
|
||
<p>VERY LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Physical functioning (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 1.8 higher (8.27 lower to 11.87 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁◯◯◯</p>
|
||
<p>VERY LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Role-physical (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 30.1 higher (7.86 to 52.34 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁◯</p>
|
||
<p>MODERATE</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Social functioning (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 1 higher (13.93 lower to 15.93 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁◯◯◯</p>
|
||
<p>VERY LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Role-emotional (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 25.1 higher (1.72 to 48.48 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁◯◯</p>
|
||
<p>LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Mental health (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 5.4 lower (18.85 lower to 8.05 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁◯◯◯</p>
|
||
<p>VERY LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Vitality (follow-up 3–6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.5 lower (14.08 lower to 9.08 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁◯◯◯</p>
|
||
<p>VERY LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL: Bodily pain (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 24.3 higher (15.95 to 32.65 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁◯</p>
|
||
<p>MODERATE</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_19_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Depression (follow-up 3–6 months; measured with: BDI (final values & change scores); range of scores: 0–63; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">55</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.12 lower (2.6 lower to 2.36 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁◯</p>
|
||
<p>MODERATE</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_21_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Hypothyroid symptoms (follow-up 6–12 months; measured with: Zulewski, signs and symptoms of hypothyroidism; Multiple scales; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">51</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">47</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">SMD 0.03 lower (0.43 lower to 0.37 higher)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁⨁</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_h_ch7.appf.tab1_1_1_2_3 hd_h_ch7.appf.tab1_1_1_2_4 hd_h_ch7.appf.tab1_1_1_2_5 hd_h_ch7.appf.tab1_1_1_2_6 hd_h_ch7.appf.tab1_1_1_2_7 hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_h_ch7.appf.tab1_1_1_2_9 hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_h_ch7.appf.tab1_1_1_2_11 hd_h_ch7.appf.tab1_1_1_1_4 hd_h_ch7.appf.tab1_1_1_1_5" id="hd_b_ch7.appf.tab1_1_1_23_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">TSH suppression (<0.4 mlU/L) (follow-up 3 months; assessed with: cases)</th></tr><tr><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_1 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_2 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_3 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab1_2">2</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_4 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_5 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_6 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup><a class="bk_pop" href="#ch7.appf.tab1_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_1 hd_h_ch7.appf.tab1_1_1_2_7 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_8 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10/130 (7.7%)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_2 hd_h_ch7.appf.tab1_1_1_2_9 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0%</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_10 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OR 8.12 (2.28 to 28.89)</td><td headers="hd_h_ch7.appf.tab1_1_1_1_3 hd_h_ch7.appf.tab1_1_1_2_11 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80 more per 1000 (from 0.03 more to 0.13 more)<sup><a class="bk_pop" href="#ch7.appf.tab1_3">3</a></sup></td><td headers="hd_h_ch7.appf.tab1_1_1_1_4 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁◯◯◯</p>
|
||
<p>VERY LOW</p>
|
||
</td><td headers="hd_h_ch7.appf.tab1_1_1_1_5 hd_b_ch7.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1</dt><dd><div id="ch7.appf.tab1_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd><dt>2</dt><dd><div id="ch7.appf.tab1_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd><dt>3</dt><dd><div id="ch7.appf.tab1_3"><p class="no_margin">zero events in both arms of one study and one arm of one study</p></div></dd></dl></div></div></div><div id="ch7.appf.tab2" class="table"><h3><span class="label">Table 9</span><span class="title">Clinical evidence profile: T4 versus placebo in older adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appf.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appf.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch7.appf.tab2_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch7.appf.tab2_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch7.appf.tab2_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch7.appf.tab2_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch7.appf.tab2_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch7.appf.tab2_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch7.appf.tab2_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch7.appf.tab2_1_1_1_1" id="hd_h_ch7.appf.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch7.appf.tab2_1_1_1_2" id="hd_h_ch7.appf.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">T4</th><th headers="hd_h_ch7.appf.tab2_1_1_1_2" id="hd_h_ch7.appf.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Placebo in older adults</th><th headers="hd_h_ch7.appf.tab2_1_1_1_3" id="hd_h_ch7.appf.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch7.appf.tab2_1_1_1_3" id="hd_h_ch7.appf.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_h_ch7.appf.tab2_1_1_2_3 hd_h_ch7.appf.tab2_1_1_2_4 hd_h_ch7.appf.tab2_1_1_2_5 hd_h_ch7.appf.tab2_1_1_2_6 hd_h_ch7.appf.tab2_1_1_2_7 hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_h_ch7.appf.tab2_1_1_2_9 hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_h_ch7.appf.tab2_1_1_2_11 hd_h_ch7.appf.tab2_1_1_1_4 hd_h_ch7.appf.tab2_1_1_1_5" id="hd_b_ch7.appf.tab2_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL (follow-up 12 months; measured with: EQ-5D; range of scores: −0.59–1; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_3 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_4 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_5 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_6 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup><a class="bk_pop" href="#ch7.appf.tab2_1">1</a></sup></td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_7 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">318</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_9 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">320</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_11 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.02 lower (0.05 lower to 0.01 higher)</td><td headers="hd_h_ch7.appf.tab2_1_1_1_4 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁◯</p>
|
||
<p>MODERATE</p>
|
||
</td><td headers="hd_h_ch7.appf.tab2_1_1_1_5 hd_b_ch7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_h_ch7.appf.tab2_1_1_2_3 hd_h_ch7.appf.tab2_1_1_2_4 hd_h_ch7.appf.tab2_1_1_2_5 hd_h_ch7.appf.tab2_1_1_2_6 hd_h_ch7.appf.tab2_1_1_2_7 hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_h_ch7.appf.tab2_1_1_2_9 hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_h_ch7.appf.tab2_1_1_2_11 hd_h_ch7.appf.tab2_1_1_1_4 hd_h_ch7.appf.tab2_1_1_1_5" id="hd_b_ch7.appf.tab2_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">QoL (follow-up 12 months; measured with: EQ VAS; range of scores: 0–100; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_3 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_4 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_5 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_6 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_7 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">318</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_9 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">320</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_11 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.1 lower (2.38 lower to 2.18 higher)</td><td headers="hd_h_ch7.appf.tab2_1_1_1_4 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁⨁</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.appf.tab2_1_1_1_5 hd_b_ch7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_h_ch7.appf.tab2_1_1_2_3 hd_h_ch7.appf.tab2_1_1_2_4 hd_h_ch7.appf.tab2_1_1_2_5 hd_h_ch7.appf.tab2_1_1_2_6 hd_h_ch7.appf.tab2_1_1_2_7 hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_h_ch7.appf.tab2_1_1_2_9 hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_h_ch7.appf.tab2_1_1_2_11 hd_h_ch7.appf.tab2_1_1_1_4 hd_h_ch7.appf.tab2_1_1_1_5" id="hd_b_ch7.appf.tab2_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Hypothyroid symptoms (follow-up 12 months; measured with: ThyPRO-hypothyroidism; range of scores: 0–100; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_3 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_4 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_5 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_6 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_7 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">318</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_9 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">320</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_11 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.1 lower (2.77 lower to 2.57 higher)</td><td headers="hd_h_ch7.appf.tab2_1_1_1_4 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁⨁</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.appf.tab2_1_1_1_5 hd_b_ch7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_h_ch7.appf.tab2_1_1_2_3 hd_h_ch7.appf.tab2_1_1_2_4 hd_h_ch7.appf.tab2_1_1_2_5 hd_h_ch7.appf.tab2_1_1_2_6 hd_h_ch7.appf.tab2_1_1_2_7 hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_h_ch7.appf.tab2_1_1_2_9 hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_h_ch7.appf.tab2_1_1_2_11 hd_h_ch7.appf.tab2_1_1_1_4 hd_h_ch7.appf.tab2_1_1_1_5" id="hd_b_ch7.appf.tab2_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Hypethyroid symptoms (follow-up 12 months; measured with: ThyPRO hyperthyroidism; range of scores: 0–100; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_1 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_2 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_3 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_4 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_5 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_6 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch7.appf.tab2_1_1_1_1 hd_h_ch7.appf.tab2_1_1_2_7 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_8 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">318</td><td headers="hd_h_ch7.appf.tab2_1_1_1_2 hd_h_ch7.appf.tab2_1_1_2_9 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">320</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_10 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch7.appf.tab2_1_1_1_3 hd_h_ch7.appf.tab2_1_1_2_11 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.2 higher (1.52 lower to 1.92 higher)</td><td headers="hd_h_ch7.appf.tab2_1_1_1_4 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<p>⨁⨁⨁⨁</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.appf.tab2_1_1_1_5 hd_b_ch7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1</dt><dd><div id="ch7.appf.tab2_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></div></div></div></div><div id="ch7.appg"><h3>Appendix G. Health economic evidence selection</h3><div id="ch7.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Flow%20chart%20of%20health%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=577228_ch7appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK577228/bin/ch7appgf1.jpg" alt="Figure 2. Flow chart of health economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Flow chart of health economic study selection for the guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or setting; non-English language</p><p>TFT; thyroid function test, FNA; fine-needle aspiration, US; ultrasound, RAI; radioactive iodine, ATDs; antithyroid drugs, Mang; management, SCH; Subclinical hypothyroidism, SCT; Subclinical thyrotoxicosis.</p></div></div></div><div id="ch7.apph"><h3>Appendix H. Health economic evidence tables</h3><p>None</p></div><div id="ch7.appi"><h3>Appendix I. Health economic analysis</h3><p>None</p></div><div id="ch7.appj"><h3>Appendix J. Excluded studies</h3><div id="ch7.appj.s1"><h4>J.1. Excluded clinical studies</h4><div id="ch7.appj.tab1" class="table"><h3><span class="label">Table 10</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appj.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appj.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Study</th><th id="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abreu 2017<a class="bk_pop" href="#ch7.ref1"><sup>1</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aghili 2012<a class="bk_pop" href="#ch7.ref2"><sup>2</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Akintola 2015<a class="bk_pop" href="#ch7.ref3"><sup>3</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review-references checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angermayr 2004<a class="bk_pop" href="#ch7.ref4"><sup>4</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Appelhof 2005<a class="bk_pop" href="#ch7.ref5"><sup>5</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cabral 2011<a class="bk_pop" href="#ch7.ref7"><sup>7</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Caraccio 2002<a class="bk_pop" href="#ch7.ref8"><sup>8</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Caraccio 2005<a class="bk_pop" href="#ch7.ref9"><sup>9</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cassio 2003<a class="bk_pop" href="#ch7.ref10"><sup>10</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cerbone 2016<a class="bk_pop" href="#ch7.ref11"><sup>11</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison. Incorrect interventions. No usable outcomes. inappropriate control group</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cooper 1984<a class="bk_pop" href="#ch7.ref12"><sup>12</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fadeyev 2006<a class="bk_pop" href="#ch7.ref13"><sup>13</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no usable outcomes matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feller 2018<a class="bk_pop" href="#ch7.ref14"><sup>14</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SR, references checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ineck 2003<a class="bk_pop" href="#ch7.ref15"><sup>15</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SR, references checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Iqbal 2006<a class="bk_pop" href="#ch7.ref16"><sup>16</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jorde 2006<a class="bk_pop" href="#ch7.ref18"><sup>18</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Koroglu 2012<a class="bk_pop" href="#ch7.ref20"><sup>20</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Li 2016<a class="bk_pop" href="#ch7.ref21"><sup>21</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mainenti 2009<a class="bk_pop" href="#ch7.ref22"><sup>22</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions. Inappropriate comparison. No placebo</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Martins 2011<a class="bk_pop" href="#ch7.ref23"><sup>23</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monzani 2001<a class="bk_pop" href="#ch7.ref26"><sup>26</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monzani 2004<a class="bk_pop" href="#ch7.ref25"><sup>25</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcome matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nagasaki 2009<a class="bk_pop" href="#ch7.ref27"><sup>27</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ng 2009<a class="bk_pop" href="#ch7.ref30"><sup>30</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population. References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nystrom 1988<a class="bk_pop" href="#ch7.ref31"><sup>31</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Parle 2010<a class="bk_pop" href="#ch7.ref32"><sup>32</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pollock 2001<a class="bk_pop" href="#ch7.ref33"><sup>33</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ross 1993<a class="bk_pop" href="#ch7.ref36"><sup>36</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes matching protocol. No control group</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ruggeri 2017<a class="bk_pop" href="#ch7.ref37"><sup>37</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Segna 2017<a class="bk_pop" href="#ch7.ref38"><sup>38</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review: study designs inappropriate. Inappropriate comparison. Incorrect interventions</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Shatynska-mytsyk 2016<a class="bk_pop" href="#ch7.ref39"><sup>39</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non-randomised controlled study</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sun 2017<a class="bk_pop" href="#ch7.ref41"><sup>41</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review: study designs inappropriate. References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taylor 2014<a class="bk_pop" href="#ch7.ref42"><sup>42</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Supplementation study in iodine deficient country. References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Teixeira 2008<a class="bk_pop" href="#ch7.ref43"><sup>43</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no usable outcomes matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Valizadeh 2009<a class="bk_pop" href="#ch7.ref44"><sup>44</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wasniewska 2012<a class="bk_pop" href="#ch7.ref46"><sup>46</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions. no usable outcomes matching protocol</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yazici 2004<a class="bk_pop" href="#ch7.ref47"><sup>47</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yetmis 2011<a class="bk_pop" href="#ch7.ref48"><sup>48</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zhao 2016<a class="bk_pop" href="#ch7.ref49"><sup>49</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zhao 2017<a class="bk_pop" href="#ch7.ref50"><sup>50</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">References checked</td></tr><tr><td headers="hd_h_ch7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zhu 2012<a class="bk_pop" href="#ch7.ref51"><sup>51</sup></a></td><td headers="hd_h_ch7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr></tbody></table></div></div></div><div id="ch7.appj.s2"><h4>J.2. Excluded health economic studies</h4><p>None</p></div></div><div id="ch7.appk"><h3>Appendix K. Research recommendations</h3><div id="ch7.appk.s1"><h4>K.1. Research question: What is the clinical and cost effectiveness of levothyroxine for people under 65 with symptomatic subclinical hypothyroidism?</h4><p><b>Why this is important:</b>
|
||
</p><p>Subclinical hypothyroidism (SCH) is a common biochemical abnormality that affects around 1% of people less than 70 years of age, rising to 6% in people in 80s. It is frequently transient and most people are asymptomatic. Large observational population surveys show that SCH is associated with increased vascular events, heart failure and mortality in younger individuals (50–70 age range). This may be because of a combination of dyslipidaemia caused by mild hypothyroidism and direct deficiency of thyroid hormone action on the myocardium. No randomised study of sufficient follow-up has been carried out that addressed the issue of long-term health outcomes in SCH. One high profile, randomised controlled trial studying the effect of sub therapeutic doses of levothyroxine (25 and 50mcg/d) in a largely asymptomatic group of older adults with SCH, on health-related QoL and symptoms at 12 months showed no clinically important benefit or harm from a low-dose of levothyroxine.</p><p>What remains unknown is whether symptomatic individuals with SCH aged <65 years could benefit from regular ‘replacement’ doses of levothyroxine both in terms of improvement in symptoms/QoL and of long-term cardiovascular events. Given the prevalence of SCH in women, it could be a major and entirely reversible cardiac risk factor but this idea remains essentially untested.</p><div id="ch7.appk.tab1" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appk.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appk.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_ch7.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_ch7.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Population: Adults 50–70 years of age with persistent symptomatic SCH, defined as TSH >5.0mIU/l, normal FT4.</p>
|
||
<p>Intervention(s): Levothyroxine ~1.0mcg/Kg/day; short duration-(?1yr) for QoL, 5yrs for major adverse cardiac events (MACE).</p>
|
||
<p>Comparison: Placebo</p>
|
||
<p>Outcome(s): symptoms, QoL (ThyPRO), MACE</p>
|
||
</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_ch7.appk.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A clinical trial would determine the effectiveness of treatment with therapeutic doses of levothyroxine for individuals aged 50–70 years. This could lead to improved treatment outcomes while minimising long-term cardiovascular risks and mortality at a very small cost.</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_ch7.appk.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This will address the lack of sufficient evidence to guide the management of symptomatic people with SCH using levothyroxine.</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_ch7.appk.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evidence of the effect of levothyroxine in people with SCH younger than 65 / 50–70 years of age would ensure clinically and cost effective treatment for those people.</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_ch7.appk.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There is a potential to improve CV event rates and mortality, which are national priorities</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_ch7.appk.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence-base is limited to a single high profile study of limited follow-up which used a low dose of levothyroxine and looked for improvement in symptoms in a largely asymptomatic population</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_ch7.appk.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This disease is over-represented in women</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch7.appk.tab1_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised, double blind placebo-controlled study of levothyroxine ~1.0 mcg/kg/d in people aged 50–70 years with persistent SCH for 3 months, 5 years intervention with MACE as the primary outcome</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_ch7.appk.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This would be an expensive study but a national ‘randomisation, mail-out tablets for 5yrs, body count’ approach through NHSCR would be feasible</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_ch7.appk.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Our experience is that GPs frequently do measure TFTs and the current evidence-base leads to uncertainty and heterogeneous practice. This was suggested to NIHR back in ~2009 when BTA was asked for research suggestions but a multicentre application led by Cardiff was not funded largely due to costs >£6M</td></tr><tr><th id="hd_b_ch7.appk.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_ch7.appk.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High. The guidelines are unable to provide clear recommendations for levothyroxine treatment for symptomatic people with SCH due to a lack of sufficient evidence. A well-executed randomised study could inform future updates.</td></tr></tbody></table></div></div></div><div id="ch7.appk.s2"><h4>K.2. Research question: What is the clinical and cost effectiveness of selenium for people with subclinical hypothyroidism?</h4><p>
|
||
<b>Why this is important:</b>
|
||
</p><p>Subclinical hypothyroidism (SCH) is a biochemical abnormality that affects around 1% of people less than 70 years of age and 6% of people at 80 years. It is frequently transient and most people are asymptomatic. Large observational population surveys show that SCH is associated with increased vascular events, heart failure and mortality in individuals aged 50–70 years. This may be because of a combination of dyslipidaemia caused by mild hypothyroidism and direct deficiency of thyroid hormone action on the myocardium. SCH has furthermore been associated with increased all-cause and cardiovascular mortality.</p><p>Public interest regarding selenium supplementation for SCH was expressed at the scoping stage of this guideline. The metabolism of thyroid hormones isinfluenced by micronutrients such as selenium. Existing studies have examined the effect of micronutrient supplementation on the concentration of thyroid hormones, and observational evidence suggests a positive association. However, data from randomized controlled trials have failed to confirm this relationship.</p><p>Within the development of the present guideline, no evidence supporting selenium as a treatment modality for SCH was identified. There remains uncertainty regarding the efficacy and effectiveness of selenium supplementation as a treatment, although public interest remains high. There is therefore a need for a high quality trial to examine its clinical and cost effectiveness for the treatment of SCH.</p><div id="ch7.appk.tab2" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appk.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appk.tab2_lrgtbl__"><table><tbody><tr><th id="hd_b_ch7.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_ch7.appk.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Population: People with subclinical hypothyroidism</p>
|
||
<p>Intervention:selenium</p>
|
||
<p>Comparison: treatment with levothyroxine/ no treatment (placebo)</p>
|
||
<p>Outcome(s): mortality, quality of life, adverse events (including cardiovascular, osteoporosis, impaired cognitive function) depression, hypothyroid/hyperthyroid symptoms, growth, TSH suppression</p>
|
||
</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_ch7.appk.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">If selenium provides clinically important benefits for people with SCH at a reasonable cost then it may be an important therapeutic modality to enhance clinical outcomes in this patient group that remains largely untreated.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_ch7.appk.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This will address the lack of evidence to guide the management of people with SCH using selenium and guide future guideline development.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_ch7.appk.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evidence of the clinical and cost effectiveness of selenium for SCH would support its delivery as medicine for SCH ensuring the effective treatment of people with this condition.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_ch7.appk.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Considering the association of SCH with increased CV events, heart failure and mortality, identifying the effectiveness of the examined treatments provides the potential to improve CV event rates and mortality which are national priorities.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_ch7.appk.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There are currently no high quality studies supporting the effectiveness of selenium in treating people with SCH to support the development of recommendations for their use.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_ch7.appk.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There are no equality issues</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch7.appk.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised, double blind placebo-controlled trial of selenium supplementation (3 months minimum duration) with long-term follow-up in people with SCH and a corresponding health economic analysis.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_ch7.appk.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High interest of patients with SCH in the effectiveness of selenium as treatment is likely to ensure the identification of an adequate sample to enable the study.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_ch7.appk.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selenium is widely available on the market in the form of dietary supplements and can be obtained without prescription.</td></tr><tr><th id="hd_b_ch7.appk.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_ch7.appk.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low. The research is of interest to patients with SCH and will target the existing lack of evidence for selenium for the treatment of SCH. However existing evidence suggests treatment of SCH in general, with conventional treatments like levothyroxine, does not result in clinically important benefits for most people.</td></tr></tbody></table></div></div></div><div id="ch7.appk.s3"><h4>K.3. Research question: What is the clinical and cost effectiveness of iodine for people with subclinical hypothyroidism?</h4><p>
|
||
<b>Why this is important:</b>
|
||
</p><p>Subclinical hypothyroidism (SCH) is a biochemical abnormality that affects around 1% of people less than 70 years of age and 6% of people at 80 years. It is frequently transient and most people are asymptomatic. Large observational population surveys show that SCH is associated with increased vascular events, heart failure and mortality in individuals aged 50–70 years. This may be because of a combination of dyslipidaemia caused by mild hypothyroidism and direct deficiency of thyroid hormone action on the myocardium. SCH has furthermore been associated with increased all-cause and cardiovascular mortality.</p><p>Public interest regarding iodine supplementation for SCH was expressed at the scoping stage of this guideline. The metabolism of thyroid hormones requires iodine as key component. Existing studies have examined the effect of iodine status and the concentration of thyroid hormones, and observational evidence suggests a positive association. However, data from randomized controlled trials have failed to confirm this relationship.</p><p>Within the development of the present guideline, no evidence supporting iodine as a treatment modality for SCH was identified. There remains uncertainty regarding the efficacy and effectiveness of iodine supplementation as treatment, although public interest remains high. There is therefore a need for a high quality trial to examine its clinical and cost effectiveness for the treatment of SCH.</p><div id="ch7.appk.tab3" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.appk.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.appk.tab3_lrgtbl__"><table><tbody><tr><th id="hd_b_ch7.appk.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_ch7.appk.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Population: People with subclinical hypothyroidism</p>
|
||
<p>Intervention: iodine</p>
|
||
<p>Comparison: treatment with levothyroxine/ no treatment (placebo)</p>
|
||
<p>Outcome(s): mortality, quality of life, adverse events (including cardiovascular, osteoporosis, impaired cognitive function) depression, hypothyroid/hyperthyroid symptoms, growth, TSH suppression</p>
|
||
</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_ch7.appk.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">If iodine provides clinically important benefits for people with SCH at a reasonable cost then it may be an important therapeutic modality to enhance clinical outcomes in this patient group that remains largely untreated.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_ch7.appk.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This will address the lack of evidence to guide the management of people with SCH using iodine and guide future guideline development.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_ch7.appk.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evidence of the clinical and cost effectiveness of iodine for SCH would support its delivery as medicine for SCH ensuring the effective treatment of people with this condition.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_ch7.appk.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Considering the association of SCH with increased CV events, heart failure and mortality, identifying the effectiveness of the examined treatment provides the potential to improve CV event rates and mortality which are national priorities.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_ch7.appk.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There are currently no high quality studies supporting the effectiveness of iodine in treating people with SCH to support the development of recommendations for their use.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_ch7.appk.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There are no equality issues</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch7.appk.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised, double blind placebo-controlled trial of iodine supplementation (3 months minimum duration) with long-term follow-up in people with SCH and a corresponding health economic analysis.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_ch7.appk.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High interest of patients with SCH in the effectiveness of iodine as treatment is likely to ensure the identification of an adequate sample to enable the study.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_ch7.appk.tab3_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Iodine is widely available on the market in the form of dietary supplements and can be obtained without prescription.</td></tr><tr><th id="hd_b_ch7.appk.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_ch7.appk.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low. The research is of interest to patients with SCH and will target the existing lack of evidence for iodine for the treatment of SCH. However existing evidence suggests treatment of SCH in general, with conventional treatments like levothyroxine, does not result in clinically important benefits for most people.</td></tr></tbody></table></div></div></div></div></div><div class="bk_prnt_sctn"><h2>Tables</h2><div class="whole_rhythm bk_prnt_obj bk_first_prnt_obj"><div id="ch7.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_ch7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_ch7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">People diagnosed with subclinical hypothyroidism (TSH greater than upper limit of context specific reference range, T3/T4 within reference range)</td></tr><tr><th id="hd_b_ch7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_ch7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T3</p>
|
||
<p>T4-initiation at high dose</p>
|
||
<p>T4-initiation via gradual titration</p>
|
||
<p>Combination of T3 & T4</p>
|
||
<p>Natural thyroid extract (mammalian only)</p>
|
||
<p>Iodine supplementation</p>
|
||
<p>Selenium supplementation</p>
|
||
<p>Placebo</p>
|
||
</td></tr><tr><th id="hd_b_ch7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_ch7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any above vs any other, in isolation or combination</td></tr><tr><th id="hd_b_ch7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_ch7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical</b>
|
||
<ul id="ch7.l1"><li id="ch7.lt1" class="half_rhythm"><div>Mortality (dichotomous, ≥1 year)</div></li><li id="ch7.lt2" class="half_rhythm"><div>Quality of life (continuous)</div></li></ul>
|
||
<b>Important</b>
|
||
<ul id="ch7.l2"><li id="ch7.lt3" class="half_rhythm"><div>Cardiovascular morbidity-ischemic heart disease, heart failure (dichotomous)</div></li><li id="ch7.lt4" class="half_rhythm"><div>Arrhythmias (dichotomous)</div></li><li id="ch7.lt5" class="half_rhythm"><div>Osteoporosis (dichotomous)</div></li><li id="ch7.lt6" class="half_rhythm"><div>Impaired cognitive function (dichotomous)</div></li><li id="ch7.lt7" class="half_rhythm"><div>Depression (dichotomous)</div></li><li id="ch7.lt8" class="half_rhythm"><div>Patient/family/carer experience of care (continuous)</div></li><li id="ch7.lt9" class="half_rhythm"><div>Healthcare contacts (rates/dichotomous)</div></li><li id="ch7.lt10" class="half_rhythm"><div>Symptom scores (continuous)</div></li><li id="ch7.lt11" class="half_rhythm"><div>Growth (continuous)</div></li><li id="ch7.lt12" class="half_rhythm"><div>TSH suppression (dichotomous)</div></li></ul></td></tr><tr><th id="hd_b_ch7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<ul id="ch7.l3"><li id="ch7.lt13" class="half_rhythm"><div>RCTs only</div></li><li id="ch7.lt14" class="half_rhythm"><div>Blinded comparisons prioritised, non-blinded comparisons only considered if blinded unavailable on an intervention by intervention basis</div></li><li id="ch7.lt15" class="half_rhythm"><div>Minimum treatment duration of 3 months</div></li></ul></td></tr></tbody></table></div></div></div><div class="whole_rhythm bk_prnt_obj"><div id="ch7.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Study</th><th id="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intervention and comparison</th><th id="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Population</th><th id="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Outcomes</th><th id="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kong 2002<a class="bk_pop" href="#ch7.ref19"><sup>19</sup></a></td><td headers="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T4: 50–100 µg daily (depending on TSH >5 µU/mL), n= 23</p>
|
||
<p>Placebo: ascorbic acid, 5 mg daily, n=17</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Women (T4 mean age 53 SD 3, placebo mean age 45, SD 4)</p>
|
||
<p>TSH 5–10 µU/mL, T4 0.8–16ng/dL; baseline TSH (µU/mL): mean (SD) T4 8 (1.5); Placebo 7.3 (1.6)</p>
|
||
<p>Symptom status: All except for two patients had self-reported symptoms suggestive of hypothyroidism; reported to have mild subclinical hypothyroidism</p>
|
||
<p>Treatment naïve</p>
|
||
<p>UK</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Symptom scores</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>80 % autoimmune thyroiditis</p>
|
||
<p>Parallel design</p>
|
||
<p>Post-treatment TSH mean (SD) (µU/mL): T4 −4.6 (2.3); placebo - 1.7 (2)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meier 2001 <a class="bk_pop" href="#ch7.ref24"><sup>24</sup></a></td><td headers="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T4: 25, 50, 75, 100 or 125 µg daily, adapted every 6 weeks to achieve euthyroid TSH (0.14.0 mlU / liter), mean dose at end of study: 85.5 SD 4.3, n=31</p>
|
||
<p>Placebo: similar dose and adjustments, n=32</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Women (T4 mean age 57.1 SD 10.34, placebo mean age 57.1 SD 10.91)</p>
|
||
<p>TSH > 5mlU/L, exaggerated TSH response of more than 35 mlU/L after oral TRH stimulation; baseline TSH range 5.0–50 mlU/L, mean (SD) TSH (mlU/L): T4 12.8 (7.79); Placebo 10.7 (5.09)</p>
|
||
<p>Symptom status: not reported</p>
|
||
<p>Treatment naive</p>
|
||
<p>Switzerland</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Symptom scores</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>50% autoimmune thyroiditis, 33% RAI or SUR for Graves’ disease</p>
|
||
<p>Parallel design</p>
|
||
<p>TSH reference range 0.1–4.0 mlU/L</p>
|
||
<p>Post treatment TSH mean (SD) (mlU/liter): T4 3.1 (1.67); Placebo:9.9 (3.94)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Najafi 2015 <a class="bk_pop" href="#ch7.ref28"><sup>28</sup></a></td><td headers="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T4: 100 µg daily, n=30</p>
|
||
<p>Placebo, n=30</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Adults (mean age: 34, SD: 10)</p>
|
||
<p>85% female</p>
|
||
<p>TSH > 4.5 mlU/L, normal FT4 (0.8–2 ng/dl), positive anti-TPO-Ab; baseline TSH (mlU/L) mean (SD): T4 8.29 (4.9) Placebo 8.12 (3.12)</p>
|
||
<p>Symptom status: symptomatic (most prevalent symptoms: weigh gain, fatigue, muscle cramp, irregular menstruation, limb numbness; no significant improvement post treatment)</p>
|
||
<p>Treatment naïve</p>
|
||
<p>Iran</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Depression TSH suppression</p>
|
||
<p>3 months</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Parallel design</p>
|
||
<p>Post treatment TSH mean (SD) mlU/L: T4 2.01 (1.34); Placebo 7.82 (5.17)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Razvi 2007<a class="bk_pop" href="#ch7.ref34"><sup>34</sup></a></td><td headers="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T4: 100 µg daily, n=100</p>
|
||
<p>Placebo, n=100</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Adults (mean age: 53.8, SD: 12)</p>
|
||
<p>81% female</p>
|
||
<p>TSH> 4mlU/L, FT4 0.7–1.9 ng/dl; baseline TSH (mlU/L) median (range): 5.3 (3.7–15.8); T4 first 5.4 (3.8–15.8); Placebo first 5.3 (3.7–13.9)</p>
|
||
<p>Symptom status: not reported</p>
|
||
<p>Treatment naïve</p>
|
||
<p>United Kingdom</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Hypothyroid-dependent quality of life TSH suppression (<0.4 mlU/L)</p>
|
||
<p>3 months</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>51% Autoimmune thyroiditis</p>
|
||
<p>Cross-over design</p>
|
||
<p>TSH reference range 0.4–4.0 mlU/L</p>
|
||
<p>Post treatment TSH median (range) mlU/liter : T4 0.5 (0.01–12); Placebo 5.2 (0.9–63.4)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reuters 2012 <a class="bk_pop" href="#ch7.ref35"><sup>35</sup></a></td><td headers="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T4: 25 mcg, 50 mcg or 75 mcg depending on stratification by TSH levels (adjusted at 2 months), n=35</p>
|
||
<p>Placebo: dose adjustment by TSH levels, n=36</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Adults (mean age: 50.01, SD:10.89)</p>
|
||
<p>TSH > 4 µU/mL, normal FT4 (0.9–1.8 ng/dL); baseline TSH (µU/mL) mean (SD) : T4 7.3 (2.3); Placebo 7.6 (2.7)</p>
|
||
<p>No information provided on previous treatment</p>
|
||
<p>Symptom status not reported</p>
|
||
<p>87.3% female</p>
|
||
<p>Brazil</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Quality of life Depression</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>68 % Autoimmune thyroiditis</p>
|
||
<p>Parallel design</p>
|
||
<p>TSH Reference range 0.4–4.0 mlU/L</p>
|
||
<p>Post-treatment TSH not reported.</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stott 2017 <a class="bk_pop" href="#ch7.ref40"><sup>40</sup></a></td><td headers="hd_h_ch7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>T4: 50 µg daily (or 25 if body weight <50 kg or known coronary heart disease), adjusted according to TSH (0.40 - 4.59 mlU/L), n=368</p>
|
||
<p>Placebo: with mock dose adjustments, n=369</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Older adults (mean age: 74.4, SD: 6.3)</p>
|
||
<p>53.7% female</p>
|
||
<p>TSH 4.60 to 19.99 mlU/L, FT4 within reference range; baseline TSH (mlU/L) mean (SD) overall 6.40 (2.01), T4 6.41 (2.01), Placebo 6.38 (2.01)</p>
|
||
<p>Symptom status: 27% asymptomatic (based on hypothyroid symptom scale)</p>
|
||
<p>Mean baseline hypothyroid symptoms score: T4 17.5 (18.8); Placebo 16.9 (17.9); Mean baseline tiredness score: T4 25.9 (20.6); Placebo 25.5 (20.3)</p>
|
||
<p>Treatment naïve</p>
|
||
<p>United Kingdom, Netherlands, Switzerland</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Health related quality of life Symptom scores</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Multicentre</p>
|
||
<p>Parallel design</p>
|
||
<p>Post treatment TSH mean (SD) (mlU/liter): T4 3.63 (2.11); Placebo 5.48 (2.48)</p>
|
||
<p>TSH at extended follow up visit mean (SD) (mlU/liter); T4 3.47 (2.08); Placebo 5.28 (2.50)</p>
|
||
</td></tr></tbody></table></div></div></div><div class="whole_rhythm bk_prnt_obj"><div id="ch7.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Clinical evidence summary: T4 vs Placebo in adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch7.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch7.tab3_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch7.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch7.tab3_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch7.tab3_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch7.tab3_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch7.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch7.tab3_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch7.tab3_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch7.tab3_1_1_1_5" id="hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Placebo</th><th headers="hd_h_ch7.tab3_1_1_1_5" id="hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with T4 (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Hypothyroid-dependent</p>
|
||
<p>T-QoL. Scale from: −3 to 1. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>100</p>
|
||
<p>(1 study)</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊝</p>
|
||
<p>MODERATE<sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: hypothyroid-dependent in the control groups was</p>
|
||
<p>−1.2</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: hypothyroid-dependent in the intervention groups was</p>
|
||
<p>0.1 higher</p>
|
||
<p>(0.16 lower to 0.36 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: General health</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊝⊝⊝</p>
|
||
<p>VERY LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: general health in the control groups was</p>
|
||
<p>7.4</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: general health in the intervention groups was</p>
|
||
<p>0.9 lower</p>
|
||
<p>(9.08 lower to 7.28 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Physical functioning</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊝⊝⊝</p>
|
||
<p>VERY LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: physical functioning in the control groups was</p>
|
||
<p>1.9</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: physical functioning in the intervention groups was</p>
|
||
<p>1.8 higher</p>
|
||
<p>(8.27 lower to 11.87 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Role-physical</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊝</p>
|
||
<p>MODERATE<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup>,</p>
|
||
<p>due to risk of bias</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: role-physical in the control groups was</p>
|
||
<p>−8</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: role-physical in the intervention groups was</p>
|
||
<p>30.1 higher</p>
|
||
<p>(7.86 to 52.34 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Social functioning</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊝⊝⊝</p>
|
||
<p>VERY LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: social functioning in the control groups was</p>
|
||
<p>0.3</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: social functioning in the intervention groups was</p>
|
||
<p>1 higher</p>
|
||
<p>(13.93 lower to 15.93 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Role-emotional</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊝⊝</p>
|
||
<p>LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: role-emotional in the control groups was</p>
|
||
<p>2.6</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: role-emotional in the intervention groups was</p>
|
||
<p>25.1 higher</p>
|
||
<p>(1.72 to 48.48 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Mental health</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊝⊝⊝</p>
|
||
<p>VERY LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: mental health in the control groups was</p>
|
||
<p>5.6</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: mental health in the intervention groups was</p>
|
||
<p>5.4 lower</p>
|
||
<p>(18.85 lower to 8.05 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Vitality</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊝⊝⊝</p>
|
||
<p>VERY LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: vitality in the control groups was</p>
|
||
<p>0.2</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: vitality in the intervention groups was</p>
|
||
<p>2.5 lower</p>
|
||
<p>(14.08 lower to 9.08 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL: Bodily pain</p>
|
||
<p>SF-36. Scale from: 0 to 100. Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>57</p>
|
||
<p>(1 study)</p>
|
||
<p>6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊝</p>
|
||
<p>MODERATE<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: bodily pain in the control groups was</p>
|
||
<p>−4.6</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol: bodily pain in the intervention groups was</p>
|
||
<p>24.3 higher</p>
|
||
<p>(15.95 to 32.65 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Depression</p>
|
||
<p>BDI (final values & change scores). Scale from: 0 to 63. Better indicated by lower values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>117</p>
|
||
<p>(2 studies)</p>
|
||
<p>3–6 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊝</p>
|
||
<p>MODERATE<sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean depression in the control groups was</p>
|
||
<p>4.88</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean depression in the intervention groups was</p>
|
||
<p>0.12 lower</p>
|
||
<p>(2.6 lower to 2.36 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Hypothyroid symptoms</p>
|
||
<p>Zulewski, other sign and symptom scale. Multiple scales. Better indicated by lower values.</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>98</p>
|
||
<p>(2 studies)</p>
|
||
<p>6–12 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊕</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean hypothyroid symptoms in the control groups was</p>
|
||
<p>2.05</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean hypothyroid symptoms in the intervention groups was</p>
|
||
<p>0.03 standard deviations lower</p>
|
||
<p>(−0.43 lower to 0.37 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>TSH suppression (<0.4 mlU/L)</p>
|
||
<p>cases</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>160</p>
|
||
<p>(2 studies)</p>
|
||
<p>3 months</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊝⊝⊝</p>
|
||
<p>VERY LOW<sup><a class="bk_pop" href="#ch7.tab3_1">1</a></sup><sup>,</sup><sup><a class="bk_pop" href="#ch7.tab3_2">2</a></sup></p>
|
||
<p>due to risk of bias, imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>OR 8.12</p>
|
||
<p>(2.28 to 28.89)</p>
|
||
</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 per 1000</td><td headers="hd_h_ch7.tab3_1_1_1_5 hd_h_ch7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>80 more per 1000</p>
|
||
<p>(from 30 more to 130 more)<sup><a class="bk_pop" href="#ch7.tab3_3">3</a></sup></p>
|
||
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1</dt><dd><div id="ch7.tab3_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd><dt>2</dt><dd><div id="ch7.tab3_2"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd><dt>3</dt><dd><div id="ch7.tab3_3"><p class="no_margin">zero events in both arms of one study and one arm of one study</p></div></dd></dl></div></div></div></div><div class="whole_rhythm bk_prnt_obj"><div id="ch7.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: T4 vs Placebo in older adults</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch7.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch7.tab4_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch7.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch7.tab4_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch7.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch7.tab4_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch7.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch7.tab4_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch7.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch7.tab4_1_1_1_5" id="hd_h_ch7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Placebo in older adults</th><th headers="hd_h_ch7.tab4_1_1_1_5" id="hd_h_ch7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with T4 (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL</p>
|
||
<p>EQ-5D. Scale from: −0.59 to 1.</p>
|
||
<p>Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>638</p>
|
||
<p>(1 study)</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊝</p>
|
||
<p>MODERATE<sup><a class="bk_pop" href="#ch7.tab4_1">1</a></sup></p>
|
||
<p>due to imprecision</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol in the control groups was</p>
|
||
<p>0.85</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol in the intervention groups was</p>
|
||
<p>0.02 lower</p>
|
||
<p>(0.05 lower to 0.01 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>QoL</p>
|
||
<p>EQ VAS. Scale from: 0 to 100.</p>
|
||
<p>Better indicated by higher values.</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>638</p>
|
||
<p>(1 study)</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊕</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol in the control groups was</p>
|
||
<p>77.4</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean qol in the intervention groups was</p>
|
||
<p>0.1 lower</p>
|
||
<p>(2.38 lower to 2.18 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Hypothyroid symptoms</p>
|
||
<p>ThyPRO-hypothyroidism. Scale from: 0 to 100.</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>638</p>
|
||
<p>(1 study)</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊕</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean hypothyroid symptoms in the control groups was</p>
|
||
<p>16.7</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean hypothyroid symptoms in the intervention groups was</p>
|
||
<p>0.1 lower</p>
|
||
<p>(2.77 lower to 2.57 higher)</p>
|
||
</td></tr><tr><td headers="hd_h_ch7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>Hypethyroid symptoms</p>
|
||
<p>ThyPRO hyperthyroidism. Scale from: 0 to 100.</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>638</p>
|
||
<p>(1 study)</p>
|
||
<p>12 months</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>⊕⊕⊕⊕</p>
|
||
<p>HIGH</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean hyperthyroid symptoms in the control groups was</p>
|
||
<p>10.3</p>
|
||
</td><td headers="hd_h_ch7.tab4_1_1_1_5 hd_h_ch7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<p>The mean hyperthyroid symptoms in the intervention groups was</p>
|
||
<p>0.2 higher</p>
|
||
<p>(1.52 lower to 1.92 higher)</p>
|
||
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1</dt><dd><div id="ch7.tab4_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></div></div></div></div><div class="whole_rhythm bk_prnt_obj"><div id="ch7.tab5" class="table"><h3><span class="label">Table 4</span><span class="title">UK costs of subclinical thyroid treatment</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK577228/table/ch7.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch7.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Drug</th><th id="hd_h_ch7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Daily dose</th><th id="hd_h_ch7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cost - month</th><th id="hd_h_ch7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cost – annual</th></tr></thead><tbody><tr><td headers="hd_h_ch7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Levothyroxine (T<sub>4</sub>), 100µg</td><td headers="hd_h_ch7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100µg</td><td headers="hd_h_ch7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£1.03</td><td headers="hd_h_ch7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£13.43</td></tr><tr><td headers="hd_h_ch7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Levothyroxine (T<sub>4</sub>), 75µg</td><td headers="hd_h_ch7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75µg</td><td headers="hd_h_ch7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£2.10</td><td headers="hd_h_ch7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£27.38</td></tr><tr><td headers="hd_h_ch7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Levothyroxine (T<sub>4</sub>), 50µg</td><td headers="hd_h_ch7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50µg</td><td headers="hd_h_ch7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£1.03</td><td headers="hd_h_ch7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£13.43</td></tr><tr><td headers="hd_h_ch7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Levothyroxine (T<sub>4</sub>), 25µg</td><td headers="hd_h_ch7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25µg</td><td headers="hd_h_ch7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£1.63</td><td headers="hd_h_ch7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">£21.25</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Source: BNF, Date, August 2019</p></div></dd></dl></div></div></div></div></div><div><p>FINAL</p></div><div><p>Intervention evidence review underpinning recommendations 1.5.1 to 1.5.6 in the guideline</p><p>Developed by the National Guideline Centre, hosted by the Royal College of Physicians</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.</p><p>Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div><div class="small"><span class="label">Bookshelf ID: NBK577228</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35129922" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">35129922</a></span></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-toc&ncbi_acc=NBK577228&ncbi_domain=niceng145er7&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK577228/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |